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CHAPTER 1: INTRODUCTION AND BACKGROUND 
Problem Summary 
Peripheral nerve injuries (PNI) are estimated to affect 20 million people in the United States making 
it a critical clinical issue [29]. This damage can lead to loss of function and sensation in the injured limb as 
well as debilitating pain [30]. Nerve injuries are often described by size; short gaps are those that can be 
repaired with direct end-to-end suturing, while critical size defects (>5mm) cannot be sutured and require 
an implant to bridge this gap, though they show some spontaneous growth [31]. The gold standard treatment 
for these injuries is an autologous nerve graft, typically harvested from sural nerves [31]. Unfortunately, 
this procedure leads to donor site morbidity and requires the patient to have multiple surgeries, and 
frequently resulting incomplete recovery. As an alternative, implants from cadavers (allografts) or other 
species (xenografts) have been attempted [32],  however, to prevent rejection, these require 
immunosuppressants which can cause additional complications [33]. 
As another approach, several models of nerve growth conduits (NGC) have been developed and 
approved for use by the FDA [7, 19, 34]. These are primarily empty tubes used to connect damaged nerve 
ends to direct them toward each other, a process initiated by growth factor release for the severed nerve 
ends and supporting glial cells. Several researchers are seeking to improve on these NGCs by adding 
features designed to promote neurite growth as well as influence attachment and growth direction. This is 
done by filling the hollow NGC with features including controlled growth factor release and a scaffold for 
cellular attachment and migration [35-38]. 
The goal of the work presented in this thesis is to enhance these simple NGCs using a combination 
of mechanical cues (compliant material), topographical cues (aligned fibers), and chemical cues (growth 
factor releasing microspheres) and test the improved NGC in combination with physical therapy.  
Structure of the Nervous System 
The nervous system gathers, transmits, processes, and stores information [39]. It is broken down 
into two main sections: the central nervous system (CNS) and the peripheral nervous system (PNS). The 
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central nervous system consists of the brain and spinal cord, while the peripheral nerves emerge from the 
CNS forming a network throughout the body similar to the vascular system [40, 41]. For this study, we are 
primarily interested in repair of damage to the PNS.  
A nerve can be described as the discrete organ of the PNS since it consists of neural components, 
connective tissue, a nutritive blood supply, and is surrounded by connective tissue [42]. Peripheral nerves 
consist of three distinct sheaths; from inner to outer they are: endoneurium, perineurium and epineurium 
[21]. The epineurium surrounds the entire nerve bundle and interacts with the other connective tissues in 
the body. It also is a supportive and protective connective tissue and carries the main supply channels of 
the interneural vascular system [43]. The perineurium is the middle connective tissue sheath that surrounds 
the nerve fibers and is made up of compact cellular layers [42]. It is a dense, mechanically strong, and 
metabolically active sheath that surrounds each fascicle [44]. The perineurium surrounds the individual 
Schwann Cells (SC) and nerve fibers. The endoneurium is a loose, soft connective tissue that embeds and 
protects the fascicles, cushioning them during the movements of the extremities. Most of the cell population 
in the endoneurium consists of SCs and endothelial cells, while fibroblasts make up only 4% [45]. 
 
Figure 1-1: Peripheral Nerve Anatomy: From the outside in you see the Epineurial sheath surrounding the entire 
nerve, including blood vessels. The inner nerve fiber bundles are surrounded by the perineurium, the individual 
fibers are surrounded by the endoneurium and myelin. Reprinted from International Review of Neurobiology, Vol 
87, Maria Siemionow, Grzegorz Brzezicki, “Chapter 8: Current techniques and concepts in peripheral nerve 
repair”, pages 141-172, Copyright (2009), with permission from Elsevier. [21] 
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Individual peripheral nerve fibers can be classified in many ways: one way is by the type of signal 
they transmit, which leads to three broad categories: sensory, motor and interneurons [46-48]. Sensory 
nerves originate from the sensory ganglia, while motor neurons originate from the somatic and autonomic 
motor neurons in the CNS [43]. Somatic motor neurons, connect to skeletal muscle fibers to provide direct 
motor function [49]. Each motor neuron terminates at several nerve fibers creating a motor unit [50]. 
Contrastingly, autonomic fibers, which control involuntary functions, create synapses in ganglion with 
secondary autonomic neurons which connect to the visceral nervous system [46, 49]. Another classification 
of nerves is efferent, going from the CNS to other organs and tissues or afferent, coming from the organs 
and tissues and sending information to the brain [48]. Interneurons work between the motor and sensory 
neurons to create a complex signaling network that provides a feedback loop [48].  
The nerve fibers within a nerve can be either myelinated (Type A and B) or not (Type C) [13, 51]. 
SCs, the ensheathing glial cells of the PNS, are critical for normal nerve function and for nerve repair. They 
constitute 90% of the nucleated cells within the peripheral nerves. There are two types of SCs: myelinating, 
Table 1-1: Nerve fiber types and properties: Size and myelination effect nerve conduction speed [13] 
 
 
Reprinted from Hand Clinics, Vol 29, Ron M.G. Menorca, Theron S. Fussell, John C. Elfar, “Nerve Physiology 
Mechanisms of Injury and Recovery”, Pages 317-330, Copyright (2013), with permission from Elsevier 
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which wrap large single nerve fibers, and ensheathing, which wrap groups of smaller nerve fibers. The 
ensheathing SC’s cytoplasmic process segregates and surrounds axons [52]. In the PNS, myelinated nerve 
fibers consist of a single axon that is enveloped by a SC and is usually larger than 1.5 µm in diameter [43]. 
The flat glial process of the SC wraps tightly around the nerve fiber several times creating a multilayer 
(myelin) sheath. Along the length of the axon, multiple SCs cover the myelinated nerve, the spaces between 
them are called the nodes of Ranvier [40]. This myelin structure allows for faster transmission of action 
potentials along the fiber by capturing the ions within the nerve fiber between the nodes [52]. A summary 
of nerve types, sizes, and conductions speeds are shown in Table 1-1.  
Different types of nerve fibers can be found in the same nerve bundle, this is referred to as a mixed 
nerve [53]. One example of a mixed nerve is the sciatic nerve: the largest single nerve in the body, it runs 
from the lower back to the legs in humans and other animals. As a mixed nerve, it contains many different 
sizes and types of nerve fibers. Studies conducted by Swett et al. showed that the sciatic nerve in one strain 
of rats contained 2005 ± 89 individual motor neuron fibers [54] and 10,500 ± 2000 sensory neuron fibers 
[55]. When considering nerve repair systems, it is important to consider the mixture of nerves types. 
Peripheral Nerve Injury 
PNI affects 2.8% of patients with trauma, presenting a critical clinical issue [56]. That comes to 
over 200,000 patients annually in the United States [57] and over one million worldwide [30]. These injuries 
often happen during traumatic accidents and are caused by mechanical, thermal, chemical or ischemic 
damage [19]. Combat veterans have an especially high occurrence of peripheral nerve injury [58] 
The bulk of our current knowledge of the aftermath of nerve injury began to accumulate with 
Augustus Waller in 1850 [43, 52]. While performing tests on frogs, Waller observed the disorganization of 
the axon and myelin sheaths distal to nerve injury. This breakdown became known Wallerian Degradation. 
After nerve injury, the nerve fibers are exposed to extracellular components leading to both 
morphological and metabolic changes occurring not only at the site of the injury, but also along the axon 
proximal and distal to the injury, in the nerve cell body, and at the distal end where the axon innervates 
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either muscle or sensory receptors [52, 53]. On the proximal side, metabolically, the neurons switch from 
a “signaling mode” to a “growing mode”[59] with protein synthesis switching from neurotransmitter-
related to axonal growth-related [60]. Growth mode includes up-regulations of neuropeptides, cytoskeletal 
proteins, and growth associated proteins [40]. Morphologically, the proximal side of the nerve degenerates 
for some distance from the injury, and then almost immediately begins to sprout new nerve fibers [61]. 
These fibers are guided by SC along the remaining endoneurium.  
We see Wallerian Degradation occur distal to the injury. Briefly, this process involves the 
degradation of myelin and  the attraction of macrophages which along with the SCs, phagocytose the 
damaged nerve material increasing the nerve gap [40]. Distal axon degradation is the beginning of the 
breakdown after PNI, however this doesn’t happen immediately. After 24-48 hours, the axons bead and 
swell leading to sudden granular disintegration of the cytoskeleton. Soon after PNI, SC in the distal stump 
begin to dedifferentiate. Within 48 hours these SCs stop producing myelin proteins, switch to neurotrophins 
and begin proliferating. These SCs play an early role in clearing myelin debris which can act as a barrier to 
axon growth [43]. Calcium influx activates calpain, a protease essential for cytoskeletal and axonal 
degradation. Disruption of the endoneurium leads to the inflammatory response which peaks 4-7 days after 
injury [52]. 
Schwann cells promote axon regeneration by secreting extracellular matrix (ECM) molecules and 
trophic factors [62]. Following nerve injury SC upregulate several neurotrophins and glial growth factor 
[30]. Along with growth promoting factors SCs secrete cytokines and chemokines that recruit immune cells 
to take over debris removal and growth factor production. Following the breakdown of the axon the empty 
endoneurium shrinks and retracts increasing the nerve gap [16]. This is followed by the formation of fibrin 
cables, which the SCs align on, forming bands of Bungner [30]. Axons extending from the proximal stump 
then grow along this SC bridge. At the outset, an excess number of axons attempt to bridge the nerve gap. 
As some reach appropriate targets in the distal stump they will enlarge and myelinate, while those that do 
not find a target will be pruned [51]. However, when gaps are large the bands of Bungner are unable to 
form, without direction, the regenerating axons never find their targets [19]. These cases require further 
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support that mimics the support provided the by the bands of Bungner. See Figure 1-2 for a visual depiction 
of Wallerian Degradation.  
 
 
Figure 1-2: Wallerian Degradation Following nerve transection injury, the axon distal to the injury breaks down.  
Macrophages and Schwann Cells are attracted to the site to clear the cellular and membrane debris.  The Schwann 
Cells then produce fibrous Bands of Bungner for the axons to follow and reconnect to their target.  If the gap is too 
large, however, the axon will not find its target without additional support. This figure has been reproduced freely 
under a Creative Commons Attribution license. © 2014 Arslantunali et al. Originally published by Dove Medical 
Press Limited  [19] 
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The effects of nerve injury are not limited to the damaged nerve: changes also occur distally at the 
nerve targets as well as proximally at synapses both in the CNS and ganglia. When motor neurons are 
injured and degrade, the associated skeletal muscle becomes denervated, losing neurotransmitter, 
neurotrophic factor and other signals [63]. The lack of stimulation results in loss of function and progressive 
muscle atrophy. Muscle fibers undergo molecular and cellular changes like gene expression and can lose 
up to 80% of their mass [63]. 
On the proximal side dorsal root ganglia (DRGs), which contain the cell bodies of the afferent 
spinal sensory system, lose trophic support from the periphery. This leads to adaptive changes including 
cell and organelle size increase, dendrite retraction, movement of the cell nucleus and a shift to synthesizing 
materials for axon repair and growth [64]. Reorganization of projections in the CNS also take place: in 
some cases they are positive, compensating for the missing input, but they may result in neuropathic pain, 
hyperreflexia, dystonia or phantom limb awareness [64]. Repairing peripheral nerves remains a challenge 
for the medical and engineering community, despite more than a century of research since Waller.  
Current Clinical Nerve Repair Strategies 
A rating system for nerve injuries was introduced by Seddon in 1942 [65] and further expanded by 
Sunderland in 1951 [19, 66]. These are summarized in Figure 1-3. As injury classification increases, more 
layers of tissue are injured or disrupted. The likelihood of recovery without intervention also decreases with 
increased grade. For this study, we most interested in Sunderland’s fifth degree injury which corresponds 
to neurotmesis, where the entire nerve trunk is transected completely and there is a scar formation. As a 
result, neuroma and Wallerian degeneration occur at the proximal and distal ends, respectively. In such 
severe injuries, surgical repair is required [19]. 
When complete disruption occurs, injuries are further divided into three categories based on size 
and the likelihood of recovery: short, long, and critical [30]. Short gaps are those that can be repaired with 
direct end-to-end suturing. Long gaps cannot be sutured and require some sort of bridging, but still show 
spontaneous recovery. Critical injuries are those that require more support than a simple bridge, these are 
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considered over 3 cm in humans and 1 cm in rats [30]. In non-critical injuries, functional repair is seen in 
6-16 wks. 
Surgical Repairs and Transplantations 
For injuries that are short enough that they will not produce tension, direct end-to-end or end-to-
side surgical connection is the gold standard and has been for over 50 years [43, 61]. However, the practice 
has existed for much longer: end-to-side nerve repair was first reported by Letievant in 1873 along with 
other surgical strategies [43]. In the past 50 years microsurgery has gone from a highly specialized 
procedure only performed at select centers to a common clinical strategy for the repair of peripheral nerve 
injury [53]. However, despite impressive technical advancements in nerve reconstruction, complete 
recovery and normalization of nerve function almost never occurs and the clinical outcome is often poor 
[45, 67-69]. 
For gaps that are too long for direct end to end connection, autologous grafts (autografts) are the 
gold standard. These grafts are often taken from sensory nerves elsewhere in the body, and are generally 
limited to about 5mm repairs due to a lack of donor nerves in the patient [30]. Autograft results in morbidity 
and often pain at the donor locations. In addition, there is often a size mismatch which can lead to 
constriction of the regenerating nerve and impede recovery [30]. The first reports of the use of autografts 
 
Figure 1-3: Peripheral Nerve Injury Classification: Seddon described three levels of peripheral nerve injury in 
1942, which was expanded by Sunderland in 1952. Reprinted from Neurosurgical Focus, Vol 16, M. G. Burnett and 
E. L. Zager, “Pathophysiology of Peripheral Nerve Injury: A Brief Review”, Pages 1-7, Copyright (2004), with 
permission from PNS Publishing group. [16] 
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were made by Philipeaux and Vulpaiin in 1870 [43]. For even larger gaps, the use of allografts, grafts from 
another individual, or xenografts, grafts from a cadaver, are required. Allografts were first reported by 
Albert around 1880 [43].  
Another strategy used to overcome the lack of autografts is to use other autologous material. One 
example of this is the vein graft which has shown some positive results when used on sensory nerves with 
noncritical defects, but these do not possess the mechanical strength to bridge critical gaps [34]. To help 
improve their mechanical strength, vein grafts have been filled with muscle fibers. The improvements seen 
with this model are attributed to the topographical cue provided by the aligned fibers and the addition of 
ECM protein that allow for cell adhesion [70]. 
Manufactured Nerve Conduits 
Nerve conduits have been used to reduce some of the complications involved with autografts and 
allografts in long nerve injuries. A nerve conduit is essentially a tube into which the distal and proximal 
end of an injured nerve are inserted. Throughout literature the terms “nerve guide,” “nerve guide conduit,” 
“nerve growth conduit,” “nerve scaffold,” “nerve tube,” and “tubilization” are used nearly interchangeably 
[71]. For this description nerve growth conduit (NGC) will be used exclusively. The first recorded attempt 
to bridge a nerve gap with a tube was made in 1880 by Gluck using decalcified bone [43]. 
 The history of NGC can be divided into three categories: non-absorbable, resorbable, and 
biomimetic. The earliest materials were non-absorbable. These include polyethylene, polyvinyl, rubber, 
tantalum metal cuffs, and in clinical practice, Gore-Tex [53]. Early results were not particularly promising; 
however, silicon conduits did lead to positive results in the clinical setting. The main downfall of non-
absorbable materials is the immune response to foreign material, which can lead to fibrosis [53]. 
The second type of nerve conduits are resorbable tubes. Numerous types have been tested and, as 
of 2014, eight had made it all the way through the FDA approval process into clinical use [19, 31, 34]. 
Clinical results as well as animal studies of most of these conduits have shown problems with 
biocompatibility, swelling and degradation rate [34]. The one that seems to show the best results in humans 
is Nuerotube, which is made from woven polyglycolic acid and is reported to be degraded in 6-12 months. 
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A 2000 study by Weber et al. showed that that this conduit performed better on short gaps than end to end 
repair and better than autografts in long gaps [72]. However, the use of hollow NGCs is currently limited 
to a critical nerve gap of approximately 4 cm [73]. 
The third and still developing generation of nerve conduits are biomimetic, meaning that they strive 
to mimic the extracellular matrix where the nerves grow naturally. This not only encompasses the material 
used for the conduit itself but also involves adding a 3D structure and molecular support to the conduit [53]. 
These allow the creation of a controlled microenvironment for the regeneration of nerve fibers and have 
shown some clinical success [74]. According to a 2012 review by Angius et al., more than 70 different 
materials have been used for nerve conduits. The most commonly used naturally derived materials are 
collagen and chitosan, while the most common synthetic material is silicone, all of which have shown 
promise in various studies [71]. Overall, nerve conduits limit myofibroblast infiltration, reduce scaring and 
neuroma formation, reduce collateral sprouting, and help concentrate neurotrophins [30]. 
Tissue Engineering Aspects of Nerve Conduits 
Engineers are trained to learn as much as they can about a problem and then use the tools they have 
to design, build and test those approaches to see how they impact the system [75]. Tissue Engineers have 
been doing this for peripheral nerve injuries for decades. Research shows that cells are highly responsive 
to cues in the surrounding environment, especially during periods of growth and development. A 
fundamental strategy in tissue engineering-based treatment approaches is to artificially recreate the 
environmental cues to influence cell behavior [39].  Several authors have reviewed these strategies in recent 
years including Arslantunali et al. [19] in 2014, Muheremu and Ao in 2015 [76], Safa and Buncke in 2016 
[77], Gaudin et al. [78] and Rbia and Shin in 2017 [79].  
Physical Characteristics 
The first aspect of a nerve conduit that needs to be considered is the physical demands that it must 
withstand. Being implanted in vivo means that it will experience stress and strain due to movement of the 
body. Additionally, it must be able to endure the temperature and chemical makeup of the body. According 
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to Nectow et. al. the factors to be considered in the mechanical design of nerve conduits are tensile strength, 
suturability, physical fit, degradation profile and swelling [34]. Tensile strength of the implant should be 
similar to that of the native tissue, for nerves that is an ultimate stress of ~11.7MPa [80]. Sundararaghavan 
et al. showed that neurites show growth preference toward soft substrates when presented with a gradient 
of stiffness [81]. Layering multiple materials is one potential solution to satisfying these conflicting 
mechanical requirements 
To prevent long-term immune response, many conduits are made from materials that breakdown 
once implanted. To be most effective, absorbable materials should be completely degraded by the time the 
nerve is repaired [34]. The conduit must not constrict the growing axon, either by collapsing or swelling, 
because this will impede nerve growth [18, 19, 47]. Additionally, the conduit needs to be porous or 
otherwise permeable to allow the free passage of nutrients and metabolites into the conduit to support neural 
and supporting cell survival and to allow the removal of waste produced by the cells [18, 47, 61, 82]. Most 
of these characteristics are achieved through the choice of material in the conduit. For this work, we are 
 
Figure 1-4: Nerve Conduit Characteristics: Several different characteristics have been added to help improve 
the functionality of nerve conduits [18]. 
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focused on adding to existing conduits that meet these requirements. Therefore, our goal is to enhance the 
conduit without compromising any of the existing features. 
Physical features of the nerve conduit can also be used to provide signals directly to the cells. 
Micron scale features act at the cellular level, while nanoscale features act at the subcellular level [83]. 
Most notable on a subcellular level for nerve regeneration is signaling to the growth cone, which is the 
leading segment of the regenerating neurites. Due to the sensitivity of neural cells to nanoscale cues, 
attention must be given to nanoscale topography in the process of tissue engineering design [39]. Few 
choices of biomaterials are truly smooth at the nanoscale, so most implanted materials present nanoscale 
cues, whether intended or not [84]. Nanoscale surface roughness has been shown to improve cellular 
adhesion to substrates [85]. Topographical cues are physical features of the substrate that influence 
individual cells. The use of this form of signal comes from knowledge about the major role that aligned 
ECM plays in guiding neural cell migration and differentiation [39]. The basement membrane on which 
axons originally grow is a three-dimensional meshwork with pores and fibers with dimensions ranging from 
tens to hundreds of nanometers [86]. Numerous in vitro studies have successfully shown that topographical 
cues significantly influence neurite outgrowth and alignment, synaptic connections, and cellular 
differentiation [87, 88].  
Cell culture experiments on topographically patterned substrates have explored the effects of 
grooves, pits, ridges, steps and waves [39]. Neurite extension can be directly guided along grooves or ridged 
surfaces in a manner resembling fasciculation, the naturally occurring process in which axons grow along 
pre-existing axons [89]. Aligned nanofibers are thought to mimic fibrous extracellular matrix proteins such 
as collagen and fibrinogen, which have similar dimensions and alignment [90]. The aligned nanofibers 
mimic the bands of Bungner and can be used to promote directed nerve regeneration by guiding glial 
migration and axonal growth [91, 92]. A study by Jiang et al. looked at the effect of the size of aligned 
nanofibers on neurite regeneration [93]. The group produced three different conduits: a control that was a 
pressed film of polycaprolactone (PCL) formed into a nerve guide, a conduit with aligned “micro-sized” 
fibers, and one with aligned “nano-sized” fibers. The two fibrous scaffolds had similar porosities, but with 
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pore sizes of 1.33 and 0.28 µm respectively. The conduits were implanted to repair a rat sciatic nerve injury 
and compared to an autograft control. At the end of three months both fibrous scaffolds showed better axon 
myelination, a measure of axon maturity, than the film conduit. However, the nanofiber conduit was 
statistically better than both the microfiber and film conduits. The nanofiber conduits also seemed to 
improve functional recovery with significantly higher compound muscle action potential amplitudes, a 
measure of muscle reinnervation [93]. It follows then that the physical surface the regenerating axons 
encounter should be a nano-scale fibrous network. 
Molecular Characteristics 
In addition to mimicking the physical characteristics of the natural environment, nerve conduits 
should also model the molecular environment. The ECM and intracellular space surrounding cells is filled 
with different molecules and we see a change in these molecular signals in response to axonal injury. Neural 
cells respond to many of these specific biochemical cues [30]. Surface-bound adhesion molecules are found 
on cell membranes and within ECM that provide binding sites able to mediate cellular attachment and 
growth [39]. The most common of these in neural tissue engineering are laminin and fibronectin [30, 39]. 
Laminin is commonly used for nerve regeneration due to its positive influence on neurite outgrowth and 
growth cone chemotaxis [34, 38]. Adhesive proteins and peptides are often absorbed or conjugated to the 
nerve conduit material or are applied as a coating. Nerve conduits containing these molecular signals mirror 
what happens in the injury environment. For example, after peripheral nerve injury, aligned Schwann cells 
secrete laminin, creating a substrate that is not only topographically oriented, but also rich in growth-
promoting adhesion molecules [39].  
Another molecule group in the neural development and regeneration environment are neurotrophic 
factors. They have been found to influence neural development, survival, outgrowth, and branching [18, 
57, 94-97]. Neurotrophic factors offer outgrowth and survival cues to the nerve that are often essential for 
full regeneration of critical defects [34]. Neurtrophins, a closely related group of neutrophic factors, made 
up of nerve growth factor (NGF), brain derived neurotrophic factor (BDNF), neurotrophin-3 (NT-3) and 
neurotrophin-4/5 (NT-4/5), have been heavily used in nerve regeneration studies [18, 34, 44, 95, 98-101]. 
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Other growth factors such as ciliary neurotrophic factor (CNTF), acidic fibroblast growth factor (aFGF), 
basic fibroblast growth factor (bFGF), glial cell line-derived growth factor (GDNF) and vascular 
endothelial growth factor (VEGF) have all also been looked at for peripheral nerve regeneration [47, 59, 
99, 102-104]. Table 1-2 provides a summary of the neural responses to neurotrophic factors. Chen et al. 
performed a study to test the synergistic effects of different types of neurotrophic factors. The study used 
eight groups: NGF alone, CNTF alone, GDNF alone, NGF+CNTF, CNTF+GDNF, NGF+GDNF, 
NGF+CNTF+GDNF, plus a control group [105]. After 12 weeks, the results showed that NGF and GDNF 
acted significantly on the survival of sensory neurons and motor neurons, respectively. CNTF was a 
dominant factor promoting cell body development, and GDNF had the most powerful effect on neurite 
outgrowth and elongation of sensory neurons and motor neurons [105]. Combined administration of the 
three factors resulted in optimal functional recovery following sciatic nerve injury in rats [105]. This study 
will examine NGF in vitro with sensory neurons and GDNF in vivo for motor and sensory neurons.  
Due to the weeks to months that it takes for injured neurons to bridge gaps and reach their targets, 
it is important to be able to provide these growth factors over an extended period of time. Direct drug 
injections can be invasive, and injected drugs tend to diffuse away from the target site, whereas 
Table 1-2: Neurotrophic factors: Neurotrophic factors have been shown to promote axonal growth and survival. 
[18]  
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biomaterials-based delivery systems can be used to non-invasively deliver drugs in a controlled and fine-
tuned manner [39]. 
Biomaterial delivery systems fall into two major categories: affinity based release, or reservoir 
based systems [106]. Affinity based system use non-covalent bonds to adhere proteins and peptides to the 
nerve conduit [107, 108]. The affect of various affinity levels in these delivery systems were tested by 
Wood et al.; they secured NGF into a fibrin matrix inside a nerve conduit using three different binding 
peptides known to have different affinities. While they didn’t see an increase in the total number of nerve 
fibers over free NGF, they did see an increase in the size and myelination of the fiber, both signs of fiber 
maturity. Size and myelination increased further with the higher binding affinity. While they did not reach 
the level of the graft control, this study does show that affinity based systems can improve nerve growth 
conduits [109].  
Reservoir based systems come in many forms and involve containing the protein within a material 
or matrix. Examples of this include micro and nanospheres, hydrogels, and nanofibers or combinations of 
these [106]. Agarwal et al. recently reported the development of a NGC that included concentric cylinders 
with space between for NGF. The inner cylinder included a single small hole for the neurotrophic factor to 
diffuse out of. They showed that animals using the conduit diffusing NGF had significantly higher muscle 
mass and muscle reinnervation at 180 days [101]. In another study, Wang et al. reported the use of 
microspheres made from poly-lactic-co-glycolic acid (PLGA) to encapsulate NGF and place it into a chitin 
nerve conduit. The results were compared to groups that received the conduit alone, the conduit with an 
NGF solution or a conduit containing empty microspheres. After three months of implantation the NGF 
microsphere group showed significantly more nerve fibers, myelin sheath thickness and axonal area. The 
empty microsphere group was not significantly different than the saline or NGF solution groups indicating 
that the presence of the microspheres was not inhibitory to nerve fiber growth [110]. 
Cellular Support 
Several groups have also incorporated cells into nerve conduits. By implanting Schwann cells it is 
thought you can speed the process of debris clearing and developing the bands of Bungner speeding and 
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increasing axonal growth [111]. SCs have also been shown to excrete neurotrophins to support nerve 
regeneration [112]. Alternatively, stem cells have been incorporated into conduits. The mechanism of stem 
cell support is not completely understood. Some studies show that the cells differentiate into neural support 
cells [113, 114]. Other studies have used vectors to modify various cell types, including Schwann cells and 
fibroblasts, to up-regulate growth factors and incorporated the cells into nerve conduits [62].  
Physical Therapy & Exercise 
As mentioned earlier, after nerve transection the muscle targets of motor neurons are left 
deinnervated leading to mechanical and biochemical changes. The benefits of physical therapy after nerve 
injury are widely accepted and routinely used in during rehabilitation following nerve injury in the clinical 
setting [115]. Exercise is known to reduce or prevent muscle atrophy and is thought to drive cortical 
remodeling [116]. However, a review of the published literature on exercise in animal models shows highly 
contradictory results, including some inhibition of reinnervation and muscle function return. This is at least 
in part due to a wide variety in the types of injuries, and the mode, intensity, duration and onset of exercise 
regimes [57, 116]. As an example, just looking at one type of injury, sciatic nerve crush, you can quickly 
find a study which used wheel running (a voluntary activity) for both three and seven days [117], another 
that used 25 minutes of swimming per day for 7 weeks [118] and a third that uses a treadmill for one hour 
per day for 14 days [119].  
Studies out of the English group however, have started to compare different modalities side by side 
to better understand how exercise affects peripheral nerve regeneration [57]. Findings showed that moderate 
exercise for two weeks resulted in longer axon regeneration than was seen in electrically stimulated or 
untrained animals in a fibular nerve transection and repair [120]. They also found an interesting gender 
difference between types of treadmill training. Female rats showed increased axon length with interval 
training but not with continuous training, while the opposite was true for males [121]. Another study 
showed that the time of the start of exercise after nerve repair changed the Hoffmann reflex (H reflex), but 
didn’t show any difference in the direct muscle response to electrical stimulus (M wave) [122]. The Navarro 
17 
 
 
 
group also looked at electrical stimulation and exercise and found that together they show a faster return of 
direct muscle response than either treatment separately [123]. In another study from that group active 
exercise (treadmill running), where the animal must initiate movement, and passive exercise (motorized 
bike), where the limbs are moved for the animal, were compared for animals with a sciatic nerve injury and 
repair [115]. Both methods showed improvement in M wave amplitude over controls, but did not show 
significant difference between the active and passive regimes. A possible explanation for the benefit of 
exercise in peripheral nerve regeneration is that neuronal factors known to promote neuronal survival are 
upregulated by increased levels of physical activity. Some of these include NT-3 and NT-4/5, GDNF, 
BDNF, and insulin-like growth factor 1 (IGF-1) and IGF-2 [124]. 
Preclinical Model: Rat Sciatic Nerve Axonotomy 
A great deal can be determined about biomaterials and treatments using in vitro testing. However, 
to date no comprehensive system that mimics the complexity of the natural environment of the nervous 
system has been developed. Therefore, a critical step in the validation of any system of peripheral nerve 
repair is in vivo testing. A systematic review by Angius et al. compiled a list of animal models that were 
used over 60 years from 1950-2010 for in vivo study of nerve regeneration [71]. They found that eight 
different species and 17 different nerves have been used. In nearly 75% of the studies rats and sciatic nerves 
where used [71]. This indicates a strong prevalence of this model, and provides a large set of data to 
compare results with. 
Savastano et. al. summarized the use of the rat sciatic nerve model for several types of injury, which 
was used at least as far back as 1906 [125]. Briefly, an incision is made in the inner thigh and the muscle is 
separated to expose the sciatic nerve. What is done at this point depends on the type of injury that you are 
trying to replicate. To model neurapraxia, an ameroid ring can be placed around the nerve which will swell 
and compress the nerve. For an axonotmesis the nerve is crushed with a tool such as forceps. For 
neurotmesis the nerve is cut with a scalpel or scissors. Depending on the treatment being tested, it may then 
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be sutured back together, have a segment removed and replaced with a conduit or have a section removed, 
inverted and replaced (a common model of autograft) [125].  
  Part of the appeal of the sciatic nerve is its ease of accessibility. It is also a mixed nerve containing 
both sensory and somatic and autonomic motor neurons. Rats show strong neural regenerative capacity. 
Beyond simple functional recovery and pain testing, the use of transgenic animals and viral vectors allows 
researchers to dig deeply into the biochemical pathways that govern many aspects of neural injury [125].  
Significance & Innovation 
Despite decades of research, regeneration and reinnervation after peripheral nerve transection 
remains a challenge. The primary standards of measure for nerve repair are functional recovery, the 
regeneration of the nerve, reinnervation of the muscle, and elongation of axons after therapy [126]. 
Researchers have tried to accomplish these goals using several methods with limited success. Bellamkonda 
et al. suggest that holistic approaches, which seek to provide combinations of cues to influence multiple 
aspects of healing and regeneration, offer great therapeutic potential in the treatment of neural injury and 
disease [39]. Two of the most promising therapeutic models are delivery of growth factors to the site and 
exercise regimens to maintain muscle tone and promote nerve activity [18, 64, 127-130]. These treatments 
have been studied individually numerous times. To our knowledge, a system that incorporates mechanically 
tuned and topographically specific substrate with direct neurotrophin delivery has not been created or 
characterized previously. Nor has that type of system been combined with physical therapy in the form of 
exercise. 
Research has shown that cells respond to several factors in their environment including mechanical, 
topographical, and chemical signals. Peripheral neurons are known to prefer a soft substrate, be directed by 
aligned fibers, and respond to neurotrophic factor [18, 34, 47]. Combining these signals into an NGC is 
hypothesized to produce a synergistic effect resulting in enhanced, directed, and accelerated neurite growth 
and thus more robust and faster functional recovery.  
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Udina et al. reviewed the current status of exercise therapy in peripheral nerve regeneration [116]. 
The published literature shows wide variance in types of injury tested, type of exercise used, duration of 
exercise, and session time of the exercise. The diversity of studies makes comparison between protocols 
difficult. However, all but one of the studies on sciatic nerve injuries showed that the exercise (swimming, 
biking or treadmill running) used was beneficial to regeneration, reinnervation, or axonal elongation [57, 
116].  
One recent study tested a collagen nerve conduit with and without Schwann cells in combination 
with exercise [131], while another did the same with mesenchymal stem cells [132]. This proposed study 
will fill an existing gap in literature determining if there is a synergistic effect of combining a NGC 
containing extended release of growth factors with physical therapy. After developing and characterizing 
an internal structure addition for NGCs combining topographical, mechanical, and chemical cues the system 
will be tested in a rat sciatic nerve injury model in combinations with exercise to model physical therapy.  
Expanding the complexity of the nerve growth conduit system and adding exercise to the treatment 
protocol is a significant step toward a highly effective nerve repair strategy. Each step that is taken lends 
hope to thousands of people that live with the debilitating reality of nerve injury; the effects of which 
include loss of muscle control or function, spasticity, and pain. Return of nerve function to these individuals 
would greatly improve their quality of life. 
Hypothesis and Specific Aims  
I hypothesize that combining a nerve growth conduit that includes chemical, mechanical, and 
topographical cues, similar to the native ECM, with physical activity will lead to a synergic effect, resulting 
in increased axonal growth and functional recovery for peripheral nerve injury patients.  
Specifically, aligned electrospun fiber, providing a topographical signal, made from cross-linked 
Methacrylated Hyaluronic Acid (MeHA), providing a mechanical cue, will be combined with microspheres 
for extended release of growth factors, providing a chemical cue, to encourage cell growth. This cellular 
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level support will further be combined with treadmill running, an active exercise regimen, encouraging use 
of the developing neurons to improve functional nerve reconnections and prevent muscle atrophy. 
To test this hypothesis two specific aims have been developed:  
1. Create, characterize, and test a NGC scaffolding based inner structure that incorporates multiple 
cell growth signaling modalities; specifically, topographical (aligned fibers), mechanical (soft substrate), 
and chemical (growth factors release).  
2. Test the effect of the developed inner structure with a nerve growth conduit system in a rat sciatic 
nerve model with and without the incorporation of an exercise regimen. Evaluating functional recovery and 
nerve regeneration through behavioral analysis, electrical signal transduction, and histological analysis. 
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CHAPTER 2: COMBINING GROWTH FACTOR RELEASING MICROSPHERES WITHIN 
ALIGNED NANOFIBERS ENHANCES NEURITE OUTGROWTH 
Portions of this chapter are contained in the publication: T.J. Whitehead, C.O.C. Avila, and H.G. 
Sundararaghavan, Combining Growth Factor Releasing Microspheres within Aligned Nanofibers Enhances 
Neurite Outgrowth. Journal of Biomedical Materials Research Part A, 2017 Sept 6. 
Tonya Whitehead was responsible for experimental design. She conducted experiments including 
microsphere preparation, scaffold preparation, SEM and ESEM imaging, cell culture, and NGF ELISA. 
She compiled and analyzed data, and assisted with manuscript preparation. 
 
Figure 2-1: Graphical Abstract. The goal of this project is to enhance the simple, hollow tube, nerve growth 
conduits (NCGs) currently available by using a combination of mechanical (soft substrate), topographical (aligned 
nanofibers) and chemical cues (growth factor releasing microspheres) to stimulate nerve regeneration. We begin 
by testing the material properties and chemical release; followed by in vitro testing of the system with dorsal root 
ganglia explants. Results show that the combination enhances and directs outgrowth for up to four weeks. 
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Introduction 
Peripheral nerve injuries are estimated to affect 20 million people in the United States making it a 
critical clinical issue [133]. This damage can lead to loss of function and sensation in the injured limb as 
well as debilitating pain. Short gaps can be repaired with direct end-to-end suturing. Critical size defects 
(>5mm) cannot be sutured and require an implant to bridge this gap, though they show some spontaneous 
growth [30]. The gold standard treatment for these injuries is an autologous nerve graft, typically harvested 
from sural nerves [30]. Unfortunately, this procedure leads to donor site morbidity and requires the patient 
to have multiple surgeries, and still often results in incomplete recovery. Alternatively, processed 
xenografts and nerve growth conduits (NGC) have been developed and approved for use by the Food and 
Drug Administration [19]. NGCs are primarily hollow tubes used to connect damaged nerve ends to direct 
them toward each other, a process initiated by growth factor release for the severed nerve ends. Several 
studies have shown that neuronal cells respond to biomaterial cues including mechanical, topographical, 
and chemical signals [38, 134]. Previously investigated modifications to NGCs were designed to promote 
neurite growth as well as influence attachment and growth direction by filling the hollow NGC with features 
including controlled growth factor release and scaffold-based cues for cellular attachment and migration 
[7, 35, 37, 135], however, few studies combine multiple cues.  
The goal of this project is to develop an internal structure that can be added to commercially 
available NGCs using a combination of chemical cues (growth factor releasing microspheres), mechanical 
cues (compliant substrate), and topographical cues (aligned fibers). Peripheral neurons are known to prefer 
a compliant substrate, be directed by aligned fibers, and respond to nerve growth factor (NGF) [82, 136]. 
We include a low-modification methacrylated hyaluronic acid as our compliant substrate and electrospin 
this material into aligned nanofibers. Controlled release of growth factors is included by immobilizing NGF 
releasing poly-lactic-co-glycolic acid (PLGA) microspheres within the fibrous network. We hypothesize 
that combining these signals into the NGC will result in increased neurite growth and thus better functional 
recovery. This manuscript describes the in vitro testing of the additional cues.  
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Materials and Methods 
Microsphere Production 
Protein was encapsulated in PLGA (Lactel, Birmingham, AL) using a Water-Oil-Water double 
emulsion technique. The 200µL inner water phase contained various concentrations of NGF from 0µg/mL 
to 100µg/mL in 1% bovine serum albumin (BSA) in phosphate buffered saline (PBS) and 4µL of 2% 
polyvinyl alcohol (PVA). This was dispersed in the oil phase of 300mg of three different ratios (50:50, 
65:35, 72:25) of PLGA dissolved in 3mL of dichloromethane (DCM) using a wand sonicator for 10 
seconds. The resulting emulsion was dispersed in the outer water phase consisting of 0.5% PVA using a 
vortex mixer and mixed on a stir plate for a minimum of 1 hour to allow the DCM to evaporate and the 
PLGA to stabilize.  The microspheres were then removed from solution by centrifugation (2000 RPM for 
10 minutes), rinsed three times, lyophilized and stored at -20 °C. 
Microsphere Characterization 
Microsphere encapsulation was quantified using BSA as a model protein and measured using a 
Comassie Blue Assay (Thermo Scientific). All remaining solutions and supernatants from the microsphere 
production process were retained and then tested for protein content following the manufacture instructions 
for the assay. Percent encapsulation was calculated as: (Initial Protein – Measure Protein)/Initial Protein. 
Microsphere size was calculated by taking brightfield images of the microspheres using a Nikon Eclipse 
inverted microscope. The dry microspheres were spread on a petri dish in a 3.3% polyethylene oxide (PEO) 
solution to prevent movement during imaging. A custom Matlab script was used to find the diameter of all 
microspheres in five images from three different samples. 
Scaffold Fabrication 
Hyaluronic Acid (ECM Science, Detroit MI) (HA) was methacrylated as previously described by 
Burdick et al. [137]. Briefly, HA was dissolved in water and methacrylic anhydride (Sigma) was added 
dropwise on ice while maintaining a basic pH using NaOH. Methacrylated HA (MeHA) was created at 
approximately 15% methacrylation, confirmed through nuclear magnetic resonance spectroscopy (NMR). 
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A solution of 2% MeHA, 3% 900kD PEO, and 0.05% Irgacure 2959 crosslinker (all w/v) was electrospun 
onto a spinning mandrel as described previously [5]. For scaffolds containing microspheres, 30mg of 
microspheres were added per milliliter of electrospinning solution.  A positive charge of 22 kV (without 
microspheres) or 24kV (with microspheres) was applied across a 15cm gap between the end of the needle 
and the rotating collection mandrel. For scaffolds with aligned fibers, the mandrel was rotated at 10 m/s, 
for random fibers the mandrel rotated at 0.5 m/s. The scaffolds were crosslinked under 10mW/cm2 365nm 
light for 30 minutes then rinsed in DI water for at least 24 hours to remove PEO, prior to use for cell seeding, 
imaging, or mechanical testing. For cell testing, they were also coated with Fibronectin (Sigma) at 5µg/cm2. 
Scaffolds of four types were fabricated: aligned fibers with microspheres (Aligned+MS), aligned fibers 
without microspheres (Aligned-MS), random fibers with microspheres (Random+MS) and random fibers 
without microspheres (Random-MS). 
Scaffold Characterization 
Mechanical Properties: Mechanical tests were performed in both dry and hydrated conditions for 
all four scaffold types described above. Fifteen scaffolds were cut into 1cm x 8cm rectangular strips, where 
the length (8cm) of the strips was parallel to the direction of rotation of the mandrel during electrospinning, 
and rinsed for PEO removal. Samples were frozen at -18°C before rapid freezing in liquid nitrogen; samples 
were then lyophilized. For dry mechanical testing, the scaffold samples were clamped in an Instron 5943 
using 120 grit sandpaper on the grips, to prevent slipping, and stretched at a strain rate of 1%/min until 
fracture. For hydrated mechanical testing, the scaffold samples were immersed in phosphate buffered saline 
(PBS) for 24 hours prior to testing and tested as described above while submerged in a PBS bath at 37°C. 
Immediately prior to testing the gage length, width, and thickness of each sample were recorded. The 
resulting stress-strain curves were recorded using BlueHill software and analyzed in Matlab. The slope of 
the linear portion of the curve was reported as Young’s modulus.  The ultimate stress was the maximum 
stress recorded for each curve. Samples that were damaged in processing or broke at the clamps were 
excluded, however all groups had n > 5. 
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Alignment: Alignment was calculated for both the dry and hydrated condition of all four scaffolds. 
For dry conditions samples (n=3) were rinsed and lyophilized. Samples were gold coated before images of 
each sample were taken using a JOEL JSM - 6510LV Scanning Electron Microscope (SEM) on high 
vacuum at 25kV. For hydrated conditions, samples (n=3) were rinsed and lyophilized, then rehydrated with 
PBS for 24hrs prior to imaging. Samples were imaged in an SEI Quanta 450FEG in environmental SEM 
(ESEM) with vacuum at 1 Torr and 10 kV beam. Alignment was determined by the OrientationJ, a plugin 
for ImageJ (NIH v1.46), which evaluates each image to find color boundaries and determine the angle that 
most lines in the image are oriented. It then produces a coherence percentage indicating the percent of the 
fibers oriented in the primary direction of the image.  
Porosity: Circular samples (n>3), 25mm in diameter and 0.5mm thick, of each scaffold were 
measured for porosity using the Archimedes’ Principle [138]. Dry samples were rinsed and lyophilized as 
described above, hydrated samples were soaked in PBS for 24 hours and patted dry prior to testing. A 
density bottle filled with ethanol (density d) was weighed (W1). A scaffold sample of weight WS was 
immersed in the density bottle. The density bottle was again filled with ethanol and weighed (W2). The 
scaffold was then immediately removed and the density bottle weighed (W3) again. The following 
parameters of a scaffold were calculated [138]: the volume of the scaffold pores (Vp , 
𝑉𝑝=(𝑊2−𝑊3−𝑊𝑠)/𝑑), the volume of the scaffold skeleton (Vs, 𝑉𝑠=(𝑊1−𝑊2+𝑊𝑠)/𝑑), the density (ρ,  
ρ=𝑊𝑠/𝑉𝑆), and the porosity (ɛ, ɛ=(𝑉𝑝/(𝑉𝑝+𝑉𝑠)).  
Degradation: Rinsed aligned scaffolds with microspheres (Aligned+MS) and without microspheres 
(Aligned-MS) were cut into circular samples 25mm in diameter and approximately 0.5mm. Each sample 
was weighed and measured prior to testing. Individual samples were placed in 5mL of PBS or 10U 
hyaluronidase in PBS and stored at 37°C [137]. Three times a week for 4 weeks all samples had the PBS 
or hyaluronidase solutions replaced. Removed solutions were stored at -20° for testing for uronic acid 
content. Each week 3 samples of each scaffold type were removed from their solution, washed in DI water 
3 times, and dried under vacuum. The dry sample weight and measurements were recorded and compared 
with the initial dry weight to determine the fractional mass remaining [35, 139]. 
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Additionally, the solution removed from the degradation bottle was tested for uronic acid, the 
byproduct of hyaluronic acid breakdown, using a carbazole colormetric test. Unknown samples and controls 
were mixed with sulfuric acid and tetraborate decahydrate over ice then heated for 10 minutes to 100°C. 
They were then cooled on ice and had a 0.125% carbazole solution added. After again heating to 100°C for 
15 minutes the samples were read at 530 nm on a plate spectrophotometer. The amount of hyaluronic acid 
that had broken down was interpolated from the uronic acid found in the unknown sample by comparison 
to the uronic acid from the know samples [137]. 
DRG Growth Analysis 
Scaffolds were attached to 12 mm methacrylated coverslips, rinsed and seeded with freshly 
harvested dorsal root ganglia (DRGs) from 9-11 day old chicken embryos. Cells were grown in cell culture 
media: Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% Fetal Bovine Serum 
(FBS), 1% Glutamate, and 1% Penicillin Streptomycin. Scaffolds not containing microspheres were 
supplemented with 50 ng/mL NGF in the media. After 5 days, the cells were fixed in 4% Paraformaldehyde 
and stained with a neurofilament antibody, an AlexaFlour 488 secondary antibody and 4',6-diamidino-2-
phenylindole (DAPI).  Images of the cells were taken using a Nikon Eclipse inverted fluorescence 
microscope and analyzed using a custom Matlab script to measure growth ratio and aspect ratio. Growth 
ratio is the number of pixels that stain positive for neurofilament divided by the number of pixels that stain 
positive for DAPI. For aspect ratio, the Matlab script creates an oval that represents the shape of the 
illuminated pixels, the reported aspect ratio is the length of the long axis of this oval divided by the short 
axis of the oval.    
Encapsulated NGF Optimization: To determine the optimal concentration of NGF for future 
experiments, 65:35 PLGA microspheres were created with 0µg/mL (n=7), 25 µg/mL (n=3), 50 µg/mL 
(n=7), 75 µg/mL(n=8) and 100 µg/mL (n=6) encapsulated NGF.  These microspheres were electrospun into 
scaffolds and seeded with DRGs and analyzed as described above.  
Aligned vs Random: Samples of Aligned + MS (n=20), Aligned – MS (n=13), Random + MS 
(n=12) and Random – MS (n=19) were fabricated on methacrylated glass coverslips. The microspheres 
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were made of 65:35 PLGA and contained 100 µg/mL of NGF. Samples containing microspheres received 
media with no NGF, while samples without microspheres received culture media containing 50ng/mL NGF. 
DRGs were seeded and analyzed as described above. 
Protein Release and Bioactivity Testing  
NGF released from the microspheres was tested by enzyme-linked immunosorbent assay (ELISA). 
Three 300 mg samples of microspheres, both with and without NGF, were incubated at 37°C in 5mL cell 
culture media. After 2 days, 1 week, and weekly thereafter for 7 weeks, the media was removed and replaced 
with fresh media.  The conditioned media was then tested for NGF by ELISA following manufacturer’s 
instructions. Additionally, the conditioned media was used to grow DRGs on tissue culture plastic to test 
NGF bioactivity as described below.  
Extended NGF Release: Freshly harvested DRGs from 9-11 day old chick embryos were placed 
directly on tissue culture plastic and grown with the conditioned media, described above, from day 2 
through week 4. Each of the three samples, for each condition, for each time point were placed on DRGs 
from three separate chicks. DRGs that did not attach, attached near the edge of the well limiting the growth 
or were damaged in the staining process were not used in the final analysis. The images were analyzed with 
the custom Matlab scripts described above. The major axis of the oval generated for the neurofilament 
channel was used as the growth distance for each image.  
Statistical Analysis 
Sample means were compared using a one-way analysis of variance (ANOVA) test and Fisher’s 
LSD post hoc analysis with statistical significance indicated at p≤0.05, unless otherwise noted.  
Results  
Microsphere Characterization and Electrospinning 
In this study, microsphere size was 18.7 ± 5.1µm and 85% of the presented protein was incorporated 
into the microspheres. The size of the microspheres can be adjusted by changing the amount of time spent 
sonicating the initial emulsion. Longer sonication results in smaller microspheres. There were no significant 
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differences in size among the three ratios of PLGA tested. Figure 2-2 shows a histogram of the microsphere 
sizes. Early studies of PLGA microspheres containing NGF reported encapsulation efficiency as high as 
95%. More recent studies have shown rates of 64% and 74% in similar applications [140-142]. 
Scaffolds of four types were fabricated for testing: aligned fibers with microspheres (Aligned + 
MS), aligned fibers without microspheres (Aligned - MS), random fibers with microspheres (Random + 
MS) and random fibers without microspheres (Random - MS). Sample images of each condition are shown 
in Figure 2-3. Microspheres were seen throughout the electrospun scaffolds, making a 3-dimensional 
fibrous network. In characterizing these scaffolds, we evaluated how the microspheres affect alignment, 
porosity, mechanical properties and neurite extension.  
Scaffold Characterization 
The addition of microspheres to the scaffolds or hydration did not significantly change the 
alignment percentages in either the random or aligned conditions (Table 2-1). Corresponding aligned and 
random conditions were significantly different with p ≤ 0.001. 
 
Figure 2-2: PLGA Microsphere Size. Histogram of PLGA microspheres sizes in bins of 5 µm from three ratios 
of Lactic:Glycolic Acid (50:50, 65:35, 75:25). Microspheres range in size from 10 µm – 45 µm, with a average of 
18.7 µm. There was no significant difference in the three groups.  
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Porosity was calculated for all conditions using fluid displacement of three-dimensional samples 
for both dry and hydrated conditions (Table 2-1). The fibers swelled from hydration, going from dry 
conditions to hydrated conditions, the porosity of the samples decreased. Aligned + MS and Aligned - MS 
decrease in porosity 26.09% and 20.39% (respectively) after hydration. Random + MS had the largest 
decrease at 48.92%, while Random – MS had the smallest at 12.45%. All conditions, except Random-MS 
were significantly different comparing dry to hydrated measurements with p ≤ 0.001. The addition of 
Table 2-1: Scaffold alignment and porosity 
 
  Aligned + MS Aligned - MS Random + MS Random - MS 
D
ry
 Alignment (%) 
56.17±2.80# 
n = 3 
59.99±12.52# 
n = 3 
18.70±10.73 
n = 3 
19.42±7.56 
n = 3 
Porosity (%) 
71.92 ±2.91 
n = 15 
71.17 ±5.36 
n = 12 
83.23 ±2.82 
n = 5 
67.03 ±8.94¥ 
n = 8 
H
y
d
ra
te
d
 
Alignment (%) 
64.43±12.31# 
n = 3 
72.25±16.32*# 
n = 3 
18.52±12.58 
n = 3 
24.02±10.62 
n = 3 
Porosity (%) 
45.02 ±6.91* 
n = 8 
50.78 ±4.15* 
n = 10 
34.31 ±12.53* 
n = 5 
54.58 ±8.22¥ 
n = 6 
* Indicates p<0.05 compared to dry in the same condition, # Indicates p<0.05 compared with random scaffolds in 
the same condition, ¥ Indicated p<0.05 compared with scaffolds with microspheres. 
 
 
Figure 2-3: SEM/ESEM Scaffold Images. Top panel shows dry electrospun MeHA scaffolds with aligned and 
random fibers with and without PLGA microspheres using traditional SEM. (scale bar=10 µm). Bottom panel 
shows scaffolds in a hydrated state using ESEM. (scale bar=50µm) 
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microspheres to the aligned conditions did not significantly change the porosity, however, the addition did 
significantly change the porosity of the random samples with p ≤ 0.001. The porosity measurements for the 
dry conditions are similar to the 50-90% porosity reported by others in literature [143].  
Bulk mechanical testing was also done on all scaffolds types both dry and hydrated (Table 2-2). 
Our mechanical testing machine is equipped with a water bath allowing us to not only test the scaffold when 
hydrated, but also submerged in PBS at 37°C. The hydrated conditions had moduli starting near the 0.50 
MPa (Random + MS) and increasing to 2.86 MPa (Aligned + MS). As expected, after hydration, all 
conditions had a significant decrease in both Young’s Modulus, from 10.48-88.99 MPa for dry conditions 
down to 0.43-2.86 MPa for hydrated conditions, and ultimate strength, from 0.71-3.75 MPa for dry 
conditions down to 0.035-0.37 MPa for hydrated conditions (p≤0.05).  
Table 2-2: Mechanical Testing 
 
  Aligned + MS Aligned - MS Random + MS Random - MS 
D
ry
 
Modulus 
(MPa) 
36.84 ±10.75# 88.99 ±19.90#¥ 19.26 ±10.91 10.48 ±2.09 
Ultimate 
Stress (MPa) 
1.72 ±0.77# 3.75 ±1.03#¥ 0.71 ±0.29 0.79 ±0.20 
n 6 5 9 8 
H
y
d
ra
te
d
 
Modulus 
(MPa) 
2.86 ±0.90* 0.95 ±0.09* 0.43±0.02* 0.76 ±0.09 
Ultimate 
Stress (MPa) 
0.31 ±0.13* 0.37 ±0.03* 0.035 ±0.009* 0.068 ±0.008* 
n 6 7 13 6 
* Indicates p<0.05 compared to dry in the same condition, # Indicates p<0.05 compared with random scaffolds in 
the same condition, ¥ Indicated p<0.05 compared with scaffolds with microspheres. 
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Degradation testing was done to confirm that the materials will break down to make room for the 
regenerating neurites. Samples of a fixed diameter were cut from Aligned + MS and Aligned - MS scaffolds. 
Three samples were placed in PBS and three in Hyaluronidase (HD). After 3 weeks, all conditions had lost 
at least half of their mass. The high rate of mass loss for samples containing microspheres is likely due to 
the breakdown of PLGA into lactic and glycolic acid. The amount of HA that was broken down during that 
time was also measured for five samples of each condition. As expected, more uronic acid, a byproduct of 
HA degradation, was released from scaffolds in the hyaluronidase than in pure PBS as seen in Figure 2-4. 
 
Figure 2-4: Degradation. A) Mass lost by Aligned+MS and Aligned-MS samples over 3 weeks in either PBS or 
hyaluronidase (HD). Samples with microspheres degraded faster likely due to the breakdown of the PLGA. B) 
Uronic acid released from Aligned+MS and Aligned-MS samples over 4 weeks. Samples in hyaluronidase (HD) 
released uronic acid, a byproduct of the breakdown of HA faster than those in PBS. 
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NGF Encapsulation 
As the concentration of NGF increased, the total amount of neurite outgrowth also increased. This 
correlation indicates that the NGF remained bioactive following production and that we could successfully 
increase the concentration of NGF within the microspheres. The quantification of neurite outgrowth area 
normalized to the DRG body area can be seen in Figure 2-5c. The 100 µg/mL condition was significantly 
different from the 0, 25, and 50 µg/mL conditions (p≤0.05). For the remaining NGF tests, the 100 µg/mL 
concentration was used because this conditioned showed the longest neurite outgrowth. 
 
Figure 2-5: NGF Encapsulation Test. Brightfield image of scaffolds with microspheres split with fluorescent 
images of DRGs with neurites stained for neurofilament antibody with FITC secondary (green) and nuclei stained 
with DAPI (blue). (A) DRGs grown on scaffolds with empty microspheres. DRGs show little outgrowth without 
NGF. (B) DRGs grown on scaffolds with microspheres filled with 100 µg/ml NGF show robust outgrowth. (Scale 
bar= 250 µm). (C) Total neurite area / DRG body area for DRGs grown on scaffolds with 0-100 µg/ml. DRG 
growth is significantly longer for 100 ng/ml compared to 0, 25 and 50 µg/ml conditions (p<0.01). Error bars 
represent standard error.  
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Aligned Fibers Enhanced and Directed Growth 
All four scaffold types were seeded with DRGs to test neurite outgrowth. For scaffolds without 
microspheres, NGF was added to the media as a positive control. Sample images can be seen in Figure 2-
6. The difference in DRG body size is due to anatomical differences in embryos that the DRGs were 
harvested from, additionally DRGs vary in size in different areas of the spinal cord [144].  
 
Figure 2-6: Sample Images of DRGs. DRGs were cultured for 5 days on aligned and random scaffolds with and 
without microspheres. Samples without microspheres were supplemented with 50ng/ml in the media. Neurite 
growth is robust in all conditions. Aligned fibers direct neurite outgrowth. (scale bar= 250 µm) 
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The DRG images on the bottom row show neurites growing along the aligned fibers primarily in 
one direction, while on the top row the neurites are growing in all directions from the neurite body on the 
random fibers. This is quantified in Figure 2-7b, where the aspect ratio for neurite growth on aligned fibers 
is significantly higher for both the microspheres and media NGF conditions when compared to the 
corresponding random fiber conditions (p≤0.05). This indicates that the aligned fibers influence the 
direction of neurite growth.  The quantification of growth ratio can be seen in Figure 2-7a. Since all the 
cells were provided with NGF it was expected that all of them would show some growth. The question was 
whether the encapsulated NGF would perform similarly to the fresh NGF in media. Analysis showed no 
significant differences in neurite growth among the four conditions indicating that NGF survived the 
production process. However, further testing was required to determine how long the NGF would remain 
functional during release.  
 
Figure 2-7: Neurite Outgrowth Quantification. (A) Neurite area, measured through neurofilament staining, 
divided by DRG body area shows no significant differences for all four conditions.  Indicating that the NGF 
released from the microspheres stimulated growth similar to the fresh NGF in media (B) Aspect ratio 
measurements of DRG growth shows alignment significantly increased the aspect ratio of DRG growth indicating 
directed outgrowth (p<0.05).  
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NGF Release  
An ELISA was used to quantify the temporal release of NGF from the microspheres for all three 
L:G ratios. The release curve obtained is shown in Figure 2-8. As expected the 75:25 PLGA had the smallest 
initial burst and slowest overall release providing a supply of NGF for nearly 4 weeks. For this reason, 
75:25 PLGA was used in the final test of NGF long term viability. 
Extended Release from Microspheres:  In this experiment, the only NGF provided to the test cells 
came from microspheres (conditioned media) that were encapsulated for days-weeks. DRG growth was 
compared to cells grown with media containing fresh NGF (positive control) and with no NGF in the media. 
The resulting growth ratios can be seen in Figure 2-9. Due to batch to batch variation in the DRGs all 
samples for a given week were normalized to the positive control. At the 2, 7, and 14-day time points the 
NGF released from the microspheres performed at or above the level of the NGF in the media. At 21 and 
28 days, the growth was to closer to the negative control condition (no NGF), indicating that the NGF had 
 
Figure 2-8: NGF ELISA. NGF release measured through ELISA for the three L:G ratios of PLGA microspheres. 
75:25 showed the slowest release of NGF. Error bars represent standard error. 
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less effect at these points. This decrease could be attributed to a reduction in the amount of NGF released 
at the later time points as seen in Figure 2-8. 
Discussion  
This study focuses on using hyaluronic acid (HA), a naturally occurring, nonimmunogenic 
biopolymer as the base biomaterial. HA is a glycosaminoglycan composed of repeating disaccharide units 
of D-glucuronic acid and N-acetylglucosamine, which is naturally increased in the extracellular matrix in 
the nervous system during embryonic development [145] and responsible for maintaining tissue 
homeostasis in the adult body [146]. HA has also been repeatedly shown to promote regeneration of 
peripheral nerves [110, 147, 148]. Additionally, HA is easily modified with methacrylates, which can be 
crosslinked to tailor the stiffness of the substrate [137].  The mechanical properties of the growth substrate 
 
Figure 2-9: NGF Extended Release Bioactivity. Neurite outgrowth for DRGs grown for 5 days in conditioned 
media by microsphere breakdown releasing NGF into the media. All conditions are normalized to the NGF Media 
condition for that time point.  Data shows that NGF released from microspheres up to 14 days performs as well or 
better then 50ng/mL of fresh NGF in the media. Error bars represent standard error. 
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has been shown to affect growth and migration in all cell types and nerves specifically have been shown to 
prefer compliant substrates [81]. When presented with a gradient of stiffness to grow on, significantly more 
neurites grew down the gradient, toward the more compliant material, than up the gradient toward the stiffer 
material [81].  For reference, rabbit tibial nerves have been shown to have a Young’s modulus of 0.50 MPa 
[80]. In this study, we were able to fabricate a fibrous HA scaffold in the range of natural nervous tissue, 
with mechanics ranging from 0.5 – 2.86 MPa when hydrated (Table 2-2). 
The hydrated state of biomaterials is rarely quantified in literature despite it being the final state of 
the material during both in vivo and in vitro experiments. Electrospun MeHA quickly absorbs water in the 
presence of PBS and swells forming a fibrous hydrogel. We used ESEM to visualize the hydrated fibers. 
We found that the topographical cues of our material remain in the hydrated state, with scaffolds continuing 
to have an aligned topography; regenerating neurons have been shown to follow topographical cues [93]. 
The porosity of the scaffold did decrease when hydrated, however, this result was not surprising due to the 
hydrophilic nature of HA. 
Cells throughout the body express growth factors and other chemical cues that can signal cells to 
migrate, proliferate and/or differentiate. Several neurotrophins, such as NGF and brain-derived 
neurotrophic factor (BDNF) have been identified to enhance and accelerate neurite growth [149, 150]. For 
this experiment NGF was selected because it has repeatedly been shown to enhance the growth of dorsal 
root ganglia (DRG), the cell type used for in vitro testing [151, 152]. Unfortunately, growth factors have 
short half-lives and, for regeneration potential, growth factors need to be delivered for several weeks to 
months. Many systems have attempted to add controlled release to electrospun fibrous networks with 
varying levels of success. These methods include blend electrospinning, emulsion electrospinning, core 
shell electrospinning and protein conjugation [153]. Each of these methods, however, have drawbacks. 
Blend electrospinning is subject to undesired distribution of factors in homogeneous aggregates. Emulsion 
electrospinning uses toxic and/or flammable organic solvents that could hinder in vivo use of the products 
[154]. Core-shell electrospinning or co-axial electrospinning has a complex design which requires precise 
control of all spinning parameters [155] and may not be feasible for large scaffolds.  
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The system tested here protects the protein using a biodegradable microsphere made of PLGA that 
is trapped within the electrospun aligned fibrous network. PLGA was selected as the microsphere material 
because its breakdown can be chemically controlled by the ratio of lactic and glycolic acid. PLGA is also 
an FDA approved polymer that has been extensively tested as a drug delivery system for NGF for more 
than two decades [156]. Micro-sized spheres were selected, rather than nano-sized, to ensure that they 
would contain enough protein to allow for sustained release and be too large to enter cells through 
endocytosis [157]. The microspheres also had to be small enough to fit through the electrospinning needle 
and be carried with the polymer to the collection site during electrospinning, while still being large enough 
to be captured in the scaffold to prevent them from moving away from the site of injury. Over time the 
microsphere shell is broken down, by hydrolysis, releasing the encapsulated protein to encourage nerve 
growth.  
Microspheres have previously been tested as a controlled delivery method both by direct injection 
into the injury site and by inserting into NGCs [158, 159]. Loose microspheres in the conduit resulted in 
unpredictable final locations of the microspheres and therefore unpredictable results [140]. When 
immobilized along the walls of a NGC, they provided a source of chemical cues but lacked the additional 
benefit of topographical and mechanical cues [160]. Having the microspheres immobilized throughout the 
scaffold creates a more uniform signal and integrating with aligned fibers allows us to combine chemical 
and topographical cues. This system also allows for patterning of microspheres within the conduit to create 
gradients to further direct cell growth and has the potential for including several chemical cues with tailored 
release profiles. Together, this scaffold has mechanical, topographical and chemical cues to encourage 
nerve regeneration.  
This system can easily be translated into a NGC for in vivo testing or clinical use.  Through 
electrospinning, we fabricate a sheet of material that can be removed from the mandrel, cut to the size 
needed and inserted into existing NCGs prior to implantation. As an alternative, we have developed a 
stepwise electrospinning process to create the entire NCG. The outer shell is electrospun first, then the 
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internal components are electrospun on top.  Finally, the material is cut to the appropriate size and rolled 
into a conduit. 
Based on the results described above, we have successfully fabricated a fibrous material, 
incorporated with PLGA microspheres, which can enhance and direct neurite growth (Figure 2-6 & 2-7). 
Our material characterization shows that scaffold fibers remain aligned and have sufficient porosity in the 
hydrated state to support nerve growth. Bulk mechanical testing of this material showed that scaffold 
properties are comparable to nerve mechanics in the hydrated state. Finally, we show that the growth factor 
remains bioactive for more than 3 weeks (Figure 2-8 & 2-9). 
Conclusions 
This study has presented an original system for production of scaffolds that provide long term 
delivery of protein. The combination of aligned fibers to provide a topographical cue, compliant substrate 
to provide a mechanically preferred environment, and protein released from microspheres to chemically 
direct the cells is a significant step toward mimicking the natural environment in vivo. The grouping of 
different modes of cell signaling shows an additive effect, improving the end result. The described scaffold 
system will next be incorporated into a NGC and tested in vivo using a rat sciatic nerve injury model. While 
the tests performed here supported the use of this system in peripheral nerve repair, changes to the 
electrospinning material and proteins incorporated could allow a similar system to be used in other tissue 
engineering environments. 
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CHAPTER 3: A NERVE GROWTH CONDUIT WITH MECHANICAL, TOPOGRAPHICAL, 
AND CHEMICAL CUES IN A RAT SCIATIC NERVE MODEL WITH PHYSICAL THERAPY 
Introduction 
On average each year, in the United States, there are 500,000 reported peripheral nerve injury cases 
[14]. These nerve injuries are divided into two broad categories: primary repair, which can be corrected 
without any additional material or tissue, and gap repair, which requires the use of additional support. Gap 
repairs can be further subdivided in to small and large gaps. Of cases that involve surgical repair 34.2% are 
large gap repairs [14]. Large gap injuries are most often repaired with an autograft, despite the fact that 
nerve growth conduits (NGC) were first approved by the FDA in 1995 (Figure 3-2) [14, 31]. Autografts 
provide a way to connect the ends of the damaged nerve in a complete nerve-specific microenvironment 
which includes extra cellular matrix (ECM), for the injured nerves to grow on, which is mechanically 
similar to the damaged nerve, and contains appropriate growth factors and supporting Schwann cells [77]. 
Unfortunately, autografts require the patient to have additional surgeries and which often results in donor 
 
Figure 3-1: Graphical Abstract. This study aims to move a step closer to solving the puzzle of large gap peripheral 
nerve repair. It tests a novel nerve growth conduit containing mechanical, topographical, and chemical cues in a rat 
sciatic nerve transection model. Physical therapy in the form of treadmill running is added as and additional cue to 
reduce muscle atrophy in support of functional recovery.  
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site morbidity, which can result in pain or loss of function. Additionally, the harvested nerves often do not 
match the size of the injured nerve which can reduce effectiveness. 
These complications create the need for an alternative method. Currently, the most commonly used 
alternative clinical treatment is a processed allograft [14]. These grafts provide the same support structure 
found in autograft, but without the supporting Schwann cells [77]. Similar to autographs, allografts may 
suffer from a size mismatch with the injured nerve. This project aims to create a manufacturable system 
that can mimic the microenvironment that exists naturally in an autograft. 
 A large body of research exists exploring tissue engineering concepts to enhance the simple hollow 
tube nerve conduit model currently available to surgeons. One strategy is to add chemical cues to the 
scaffold in the form of growth factors [142, 161, 162]. Santos et al. described the production of microsphere 
incorporating various neurotrophins (NGF, BDNF and GDNF). The results of putting microspheres in the 
center of a nerve conduit were compared with delivering the growth factor to the conduit in solution. The 
use of locally-delivered microspheres significantly increased the number of regenerating axons. Another 
 
Figure 3-2: Frequency of Methods of PNI Repair by Injury Size. PNI can be broken down into three categories: 
No Gap, Small Gap, and Large Gap. The frequency of each repair strategy used for each gap size is described. 
Hollow tube connectors, also known as nerve growth conduits, are used primarily in small gap repairs. As the gap 
size increases the use of processed nerve allograft and autografts become more common. This figure was originally 
published in the Analysis of the Peripheral Nerve Repair Market in the United States, 2012 by Magellan Medical 
Technology Consultants, Inc. and was reproduced freely as part of the public domain.[14]  
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modification is to provide topographical cues within the scaffold through the use of nanofibers [163-166]. 
Creating aligned fibers helps to guide the axon toward its target. Additionally, nerve cells are known to 
prefer soft substrates; this can be taken advantage of by carefully selecting the material used as a substrate. 
As these cumulative modifications are made, the fundamental needs of the conduit must also be considered. 
Many review articles have also discussed the need for the conduits to be porous to allow the passage of 
nutrients, providing electrical stimulation, and including support cells [18, 19, 77, 101, 167]. It is also noted 
that combining signals could increase the productivity of the conduit [18, 19, 39]. 
This study incorporated several of the modifications mentioned above into a single nerve growth 
conduit, which is one step closer to simulating the nerve-specific micro environment that make autografts 
the gold standard of repair. We combined a resorbable outer conduit, with a nerve-specific internal structure. 
The inner structure consisted of methacrylated hyaluronic acid (MeHA), an ECM protein with mechanical 
properties comparable to those of nerve tissue. The MeHA was electrospun into aligned nanofibers, which 
provide a topographical signal to direct the regenerating axons toward their target at the other end of the 
conduit. Chemical cues, specifically glial-cell derived neurotrophic factor (GDNF), are delivered through 
microspheres, which act as a reservoir, releasing the proteins as the microsphere shell breaks down.  
Other factors outside the immediate micro environment of nerve regeneration can affect the 
outcomes following peripheral nerve injury. During chronic denervation, muscles will atrophy from lack 
of use. Physical therapy, both active and passive, can help to reduce this muscle loss, which leads slow and 
incomplete functional recovery [115]. Additionally, exercise leads to the upregulation of some neurotrophic 
factors which can support nerve regeneration [168]. To see if these benefits have an additional effect on 
recovery, physical therapy in the form of treadmill running, an active exercise, was added to the treatment 
protocol for some groups.  
43 
 
 
 
Materials and Methods 
Animal Study Design 
 A power analysis was conducted based on results seen by Jin et al.. for Compound Muscle Action 
Potential (CMAP) [147] and Xu et al for functional testing [169] using alpha = .05 and Power = .80. 
Functional tests indicated the need for four animals per groups, while CMAP indicated the need for eight. 
Nine animals per group was selected for this study to ensure significance in all testing and to allow for the 
possibility of loss of animals prior to CMAP recording. 
Forty-five female Lewis rats weighing ~135g were purchased from Envigo. The animals were 
divided randomly into five testing groups: 1) conduit with MeHA aligned fibers (Fibers); 2) conduit with 
MeHA aligned fibers with physical therapy (Fibers + PT); 3) conduit with MeHA aligned fibers and GDNF 
microspheres (Fibers + GF); 4) conduits with MeHA aligned fibers, GDNF microspheres, and physical 
therapy (Fibers + GF + PT); 5) Autologous graft control (Autograft). A summary of the groups can be seen 
in Table 3-1. All work with animals was approved by the Wayne State University Institutional Animal Care 
and Use Committee. 
Microsphere Production 
GDNF was encapsulated in poly-lactic-co-glycolic acid (PLGA - Lactel, Birmingham, AL) using 
a Water-Oil-Water double emulsion technique. The 200µL inner water phase contained 100µg/mL GDNF 
in sterile water and 4µL of 2% polyvinyl alcohol (PVA). This was dispersed in the oil phase of 300mg of 
75:25 PLGA dissolved in 3mL of dichloromethane (DCM) using a wand sonicator for 10 seconds. The 
resulting emulsion was dispersed in the outer water phase consisting of 0.5% PVA using a vortex mixer for 
60 seconds then placed on a stir plate for a minimum of 1 hour to allow the DCM to evaporate and the 
Table 3-1: Group Descriptions 
Group Surgical Treatment Growth Factor Physical Therapy n 
Auto Autograft None None 9 
Fibers Only Conduit with MeHA Fibers None None 9 
Fibers + PT Conduit with MeHA Fibers None Treadmill 9 
Fibers + GF Conduit with MeHA Fibers GDNF None 9 
Fibers + GF + PT Conduit with MeHA Fibers GDNF Treadmill 9 
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PLGA to stabilize.  The microspheres were then removed from solution by centrifugation (2000 RPM for 
10 minutes), rinsed three times, lyophilized and stored at -20 °C until use [5, 170]. 
Conduit Production 
 For the outer layer of the conduits, 6% w/v 80 kDa polycaprolactone (PCL) was dissolved in 
hexafluoropropylene (HFP) and electrospun at 13kV with a flow rate of 1mL/hr onto a mandrel spinning at 
10m/s to create aligned fibers to a thickness of ~250µm. The sheet was then removed and cut into 14mm x 
10mm pieces. These pieces were later rolled so that the fibers were oriented around the circumference of 
 
Figure 3-3: Conduit Schematic and Macro Images. A) The conduit consists of aligned fibers for topographical 
and mechanical cues containing microspheres that release growth factors to provide a chemical cue.  B) The 
finished conduit. C) A conduit immediately following implantation to repair a 8mm nerve gap.  
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the conduit. To add the inner layer, which consisted of methacrylated Hyaluronic Acid (MeHA) fibers or 
MeHA fibers with MS depending on the test group, the PCL pieces were placed back on the collection 
mandrel so that their fibers were parallel to the axis of the mandrel. Custom made masks, with voids the 
length and circumference of inner surface of the conduit were placed over the PCL, so that the MeHA only 
deposited on the PCL in the area that would become the inner surface of the PCL conduit. MeHA, with and 
without microspheres, was electrospun as previously described [170]. Briefly, a solution of 2% MeHA, 3% 
polyethylene oxide PEO, and 0.5% Irgacure 2959 photoinitiator was spun at 22kV, for fibers only, or 24kV 
for fibers with MS, at a flow rate of 1.2mL/hr onto a mandrel spinning at 10m/s to create aligned fibers to 
a thickness of 250µm. The individual pieces were removed and the custom masks were carefully cut off. 
The MeHA fibers were thus perpendicular to the PCL fibers. The unrolled conduits were crosslinked for 
30 minutes under 10mW/cm2 365nm light. They were then rolled, and the edge was sealed with tissue 
adhesive, N-butyl-2-cyanoacrylate [161]. The resulting conduits were 14mm long, with 10 mm of fibers on 
the inner surface, and an inner diameter of 1.3mm. Conduits were sterilized through low temperature 
ethylene oxide exposure over two days and sealed in sterile containers.  Containers were opened 24 hours 
prior to implantation surgery in a sterile environment to add sterile phosphate buffered saline (PBS) which 
dissolved the PEO carrier in the inner layer.  
Implantation Surgery 
 The rats were given sub-cutaneous (SC) injection of sustained release Buprenex (0.5 mg/kg) for 
pre-emptive analgesia at least 30 minutes before surgery.  Rats were then anesthetized using 5% isoflurane 
in oxygen at 1 liter/minute and maintained under anesthesia with 1.5-2.5% isoflurane.  Ointment was 
applied to the eyes to prevent drying. The surgical site was shaved and cleaned.  The animal was then placed 
on a water circulating heating pad covered and draped with sterile towels so that only the surgical region is 
exposed.  Following aseptic procedures, a dorsal lateral skin incision was made on the left hind limb 
between the lateral aspect of the knee joint and greater trochanter of the femur bone to expose muscles and 
fascia. The skin was separated from the superficial fascia exposing the muscle. A gap was then created in 
the thigh muscle (biceps femoris) to expose the sciatic nerve.  
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For the autograft group, a 10 mm segment was removed from the sciatic nerve, reversed, and 
immediately sutured back in place with four to six epineural sutures of monofilament polyamide (8-10/0 
Ethilon).  For treatment groups an 8 mm section of the nerve will be removed, the remaining ends were 
inserted 2 mm into the nerve conduit (described above) so that they reached the inner scaffolding. The 
conduits were sutured in place with two sutures per end of monofilament polyamide. The muscle fascia 
was closed with 3-0 absorbable sutures, then the skin incision was closed with stainless steel wound clips. 
The rats were then removed from isoflurane and a thin layer of metronidazole in New Skin as described by 
Zhang et al. [171] was applied to the toes of the left foot to prevent autophagia. They also received SC 
injections of carprofen (5mg/kg) and lactated ringers (3% of body weight (g)) immediately following 
surgery. Rats were kept on the water circulating heating pad until alert. Oral Gabapentin (100mg/kg) was 
then administered.  
Post-Surgical Care 
Following surgery, SC carprofen was administered for two days, oral Gabapentin was administered 
for five days, and Metronidazole and New Skin topical was applied every four days throughout the study.    
Animals were monitored twice daily for dehydration and skin lesion for 2 weeks, then once daily for the 
duration of the study. They were kept on soft bedding to reduce the likelihood of pressure sores developing 
on the injured limb from altered stance. Additional enrichments were provided for the animals post-surgery 
to further deter them from autophagia or chewing at the incision site.  Weekly, each animal received a novel 
chew, each day of the week they received a different foraging treat in addition to their standard feed. Wound 
clips were removed 10-12 days following surgery.  
Testing Acclimation and Exercise Treatment 
 At least five times prior to surgery all animals were taken to the testing and exercise room for 
acclimation. They were placed in testing equipment, without any test being run and allowed to explore for 
at least 5 minutes to become comfortable with the environment. Prior to surgery, all animals were also 
given at least five training sessions with the treadmill prior to surgery, lasting 10 minutes each.  
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 After surgery all animals were taken to the exercise room 5 days a week. Animals in exercise groups 
were placed on the treadmills for two 30 min sessions, with a 10 min break between where they were 
returned to their cage [115]. The treadmill speed was 5m/min. Animals in non-exercise groups were placed 
on non-running treadmills for the same durations.  
Behavior and Functional Testing 
 One week prior to implantation surgery (baseline) and weekly starting one week following surgery 
all animals underwent the following behavioral and functional tests. Researchers performing tests were 
blinded to the treatment the animals received.  
Static Sciatic Index: Rats were placed in individual plexiglass containers with a video camera 
underneath.  After the animals were allowed to acclimate for 5 minutes, the rat’s stance was recorded for 2 
minutes. Individual frames were extracted from the video and given codes to blind researchers.  The 
following parameters were measured from the images at each time point: Print Length (PL) from the tip of 
the third toe to the heel; Toe Spread (TS) the distance between the tip of the first and fifth toes; and 
Intermediate Toe Spread (ITS) the distance between the tips of the second and forth toes. Measurements 
were taken of both the experimental (O) side and contralateral side (N). The following ratios were then 
calculated:  
Toe spread factor (TSF) = (OTS – NTS) / NTS 
Intermediate toe spread factor (ITSF) = (OITS – NITS) / NITS 
Print length factor (PLF) = (OPL – NPL) / NPL 
The static sciatic index (SSI) was then calculated using the following equation: 
SSI = (108.44 x TSF) + (31.85 x ITSF) – 5.49 [172, 173] 
Ladder Walking (Footfall): A ladder was constructed as described by Bolton et al. [174]. The ladder 
was 1 meter long by 5 cm wide with thin smooth metal bars with spaces between the bars varying in width 
between 1.5 and 4 cm. The ladder was mounted ~4 feet above the ground to prevent animals jumping off. 
Figure 3-4A shows the ladder used for testing. Animals were allowed to walk back and forth across the 
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ladder at their own pace. The number of footfalls were recorded for each hind limb on three passes across 
the ladder. The total number of misses for the experimental side for each time point is presented.  
Von Frey filament test (mechanoreceptor test): The von Frey filament mechanoreceptor test was 
carried out as described by Schaeffer et al. [175]. A single tester performed all hindpaw withdrawal testing 
and was blinded to the surgical procedure used on the sciatic nerve. For each session, following 5 min of 
acclimation in an acrylic box placed on a wire mesh platform, rats were stimulated on the plantar surface 
of each hindpaw using von Frey filaments ranging from 0.4 to 60 grams (Figure 3-4B). Each filament was 
applied for a period of 1-2 seconds and repeated three times at 4-5 second intervals. The threshold for paw 
withdrawal was recorded as the filament that produced a paw withdrawal three consecutive times. Values 
were reported as ratios of experimental side force required for response to contralateral side force required 
for response.  
Figure 3-4: Ladder Walk and von Frey Testing Equipment. A) Ladder walk setup: Subjects walked across the 
ladder three times while the number of times they missed a rung was recorded. B) Von Frey testing setup: Subjects 
were placed in a acrylic box with a mesh bottom. After a minimum of 5 minutes acclimation increasing strengths 
of fibers were applied to the animals hind foot until they withdrew their paw.   
A B 
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Electrophysiological Recording and Tissue Harvest 
Two months following implantation surgery animals were anesthetized using 5% isoflurane in 
oxygen at 1 liter/minute and maintained under anesthesia with 1.5-2.5% isoflurane.  Ointment was applied 
to the eyes to prevent drying. The animal was placed on a heating pad then bilaterally the surgical site was 
shaved and cleaned. A dorsal lateral skin incision was made on each hind limb between the lateral aspect 
of the knee joint and greater trochanter of the femur bone to expose muscles and fascia. The skin was 
separated from the superficial fascia, exposing the muscle. A gap was then created in the thigh muscle 
(biceps femoris) to expose the sciatic nerve. The proximal aspect of the gastrocnemius muscle was 
identified at the posterior part of the knee joint. The bony protuberance at the distal end of the gastrocnemius 
was cut to detach the muscle from the foot. For stimulation, a custom-made hook electrode was placed 
under the sciatic nerve above the implanted conduit.  Recording electrodes were made of stainless steel 
wire insulated by Teflon coating except for a bare tip of about 2 mm. A pair of recording electrodes were 
implanted via a 22- gauge needle into the midbelly regions of the gastrocnemius muscle with insertion 
direction proximally from the posterior part of the knee joint distally into the muscle. A ground electrode 
was placed on the tail of the rat. Prior to stimulation, a force transducer was attached to the detached distal 
end of the gastrocnemius muscle to record muscle contractile force produced by the electrical stimulation. 
Electrode and transducer placement can be seen in Figure 3-5. To evoke CMAPs, increasing electric 
stimulations of 0.1 – 15 V were administered for 0.3ms to the sciatic nerve at the firing rate of 1 Hz. Each 
voltage step was induced at minimum 10 times before moving to the next voltage.  Neural activity EMG 
and force transducer output were recorded using a Biopac MP36 Data Acquisition Unit. The recordings 
were then repeated on the contralateral side.   
Following recording, a 15 mm section of both sciatic nerves was removed, photographed, and fixed 
and stored in 4% paraformaldehyde until preparation histological and immunohistochemistry analysis. The 
gastrocnemius muscle was also collected bilaterally, weighed, then fixed and stored in 4% 
paraformaldehyde. The animals were sacrificed with an intraperitoneal overdose of sodium pentobarbital.  
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Electrophysiological Recording Analysis 
 A custom Matlab script was used to analyze the CMAP and muscle contractile data. First, the 
stimulation channel was normalized to a mean value of zero volts between stimulation spikes. The exact 
location of the stimulations was identified and used to designate processing blocks in the CMAP and muscle 
force channels. For muscle contractile force, the maximum voltage recoded following each stimulation was 
identified and averaged over all stimulations for each input voltage.  Finally, the lowest voltage to result in 
a muscle contraction and which voltage resulted in the strongest contraction was determined for each leg 
of each animal.  
 For CMAP recordings, signals were filtered individually in the 900 ms following the stimulation. 
The filtered data was used to determine the time when the signal returned to neutral after stimulation. The 
latency from stimulation to peak of action potential, the area under the positive portion of the curve, the 
overall amplitude, and the overall duration of the action potential were calculated for each animal at each 
stimulation voltage (Figure 3-6). Averages of all factors were determined over all stimulations for each 
input voltage.  Additionally, the minimum voltage required to stimulate a response and the voltage that 
elicited the strongest response were determined for each leg of each animal. 
 
Figure 3-5: Electrode and Force Transducer Placement. A blue custom hook electrode was placed around the 
nerve proximal to the injury site (blue arrow). The recording electrodes are imbedded into the gastrocnemius 
muscle (green arrow) to record CMAP signals. A force transducer was also attached to the distal end of the 
gastrocnemius muscle to record muscle contractile forces (white arrow).  
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Histology and Immunohistochemistry  
 Several histological and immunohistochemistry preparations were undertaken to examine tissue 
health, nerve regeneration, myelination, and support cell presence.   
Hematoxylin and Eosin (H&E): Harvested nerve segments were dehydrated through increasing 
ethanol (EtOH) and xylene passages, then embedded in paraffin. The nerve tissue was sectioned 
longitudinally at 7µm thickness. Paraffin was removed from the tissue sections through multiple 
submersions in xylene. The tissue was then rehydrated through a decreasing EtOH gradient and deionized 
water. The tissue sections were stained with hematoxylin for 1 min, then dipped in eosin Y. The stained 
samples were rinsed with tap water, dehydrated through an increasing EtOH gradient and xylene, then 
mounted using DPX.  
 
Figure 3-6: CMAP Calculations. Several measurements were taken from each stimulation applied to the nerve. 
A) The latency, which was measured as the distance from the stimulation pulse to the peak of the action potential 
response. B) The area under the action potential curve. C) The amplitude of the action potential, measured from the 
highest to lowest points. D) The duration, measured from the onset of the action potential until the signal stabilizes 
again. 
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Anti-Neurofilament Light: Longitudinal sections of nerve were prepared as described under H&E. 
Following rehydration slices were incubated in 1% hydrogen peroxide (H2O2) for 1 hour; they were then 
rinsed with phosphate buffered saline (PBS). A solution of primary antibody for light chain neurofilament 
(Millipore ab9568) with 1% bovine serum albumin (BSA) and 2% normal goat serum (NGS) diluted in 
PBS was placed on the slides for 48 hrs at 4ºC. Control slices received a solution with only 1% BSA. After 
rinsing with PBS the primary antibody was bound with secondary antibody containing horseradish 
peroxidase (HRP) (Abcam ab6721) for 1.5 hours. Samples were rinsed with PBS then allowed to react with 
3,3′-Diaminobenzidine (DAB) for 5 minutes. Once color developed they were rinsed and mounted and 
imaged as described above.   
Anti-Neurofilament Intermediate and S100: Longitudinal sections of nerve were prepared as 
described under H&E. Following rehydration slices were rinsed in wash solution (1% BSA, 0.5% Triton-
X) three times. They were then incubated for 1 hour in 10% NGS for blocking. A solution of primary 
antibody for intermediate chain neurofilament (Sigma N5389) and S100 (Sigma S2644) was placed on the 
slides overnight at 4ºC. Control slices received a solution with only PBS. After rinsing with PBS the primary 
antibody for neurofilament was bound with secondary antibody with an Alexa flour 488 tag (green) and 
S100 was bound with CF 568 (red) for 1 hour. Finally, DAPI was added for 5 minutes to stain cell nuclei 
blue. After rinsing with PBS slices were imaged  with a Nikon Eclipse inverted microscope. 
Osmium Tetroxide (OsO4): The harvested nerves were first rinsed with PBS for 10 minutes. The 
nerve sample was cut into 3 equal pieces, keeping track of the position and proximal end of each piece. 
They were then placed in a 2% solution of OsO4 for 2 hours, followed by dehydration with 3 rinses of each 
step of an extended EtOH and xylene gradient as described by Di Scipio et al. [176]. The 3 pieces of each 
nerve sample were then embedded in the same paraffin block so that the proximal end of each piece was 
oriented in the same direction. They were then sliced transversely and rehydrated, stained with H&E, and 
mounted as described above.  
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Statistical Tests 
 One-way ANOVA with Fisher’s LSD post hoc testing was used to compare groups at each time 
point. Significance is reported as p < 0.05. Error bars represent standard error unless otherwise noted. 
Results 
Conduit 
 Two different types of conduits were produced. Each had an overall length of 14 mm to allow the 
injured nerve to be inserted 2 mm. The outer shell was made of PCL. The inner diameter of the PCL layer 
was 1.3 mm which is slightly larger than the injured nerves to prevent the regenerating nerve from being 
pinched. The first conduit type contained an inner structure of only aligned MeHA fibers. The second 
conduit type contained an inner structure consisting of aligned MeHA fibers with GDNF microspheres 
captured within the fibrous structure. A cross-section of those conduits prior to hydration and rinsing can 
be seen in Figure 3-7. Conduits were also produced without the GDNF microspheres as a negative control. 
Conduits were implanted into Lewis rats that underwent the following testing. 
 
Figure 3-7: Conduit SEM. A) Shows a cross section of the center of a completed conduit. The inner MeHA and 
MS layer is indicated with a blue arrow. B) A higher magnification of the MeHA inner structure shows that MSs 
are found throughout the depth of the internal fibers. Three at different depths are indicated with blue arrows.  
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Ladder Walking 
 Prior to surgery and weekly following surgery all subjects were allowed to walk across a ladder. 
Observers recorded the number of times each animal missed a rung over three passes (Figure 3-8). At 1 
week Fibers was significantly different from Fibers + PT and Fibers + GF was different from Fibers + GF 
+ PT, indicating the physical therapy is having some effect. At week 2 Fibers + PT was significantly 
different than all groups except Fibers. During several weeks both Fibers + GF and Fibers + PT were 
significantly different from the Fibers group. This indicates that both the physical therapy and the GDNF 
were both having a positive effect. Autograft group animals returned to counts similar to baseline within 3 
weeks. In week 4 the groups with GDNF were near the autograft group. By week 5 the Fibers + PT group 
 
Figure 3-8: Footfall Test. Prior to surgery (0) and weekly after surgery animals (n=9) walked across a horizontal 
ladder and the number of times they missed a rung was recorded. Lower scores indicated better gross motor skills 
in the injured leg. All groups showed improvement over the duration of the study, with autograft improving fastest 
followed by GF groups. Statistical significance (p < 0.05): # Fibers + PT differ from Fibers; $ Fibers + GF differ 
from Fibers; * Fibers + GF + PT differ from Fibers + PT; ¥ Fibers + GF + PT differ from Fibers + GF. This 
indicates that both the PT and GF have some effect on the functional recovery. 
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also had a low number of misses. Fibers were significantly different from all other groups for weeks 3, 5, 
and 8.  
von Frey Fibers 
 In addition to gross motor function provided by motor neurons, functional recovery requires the 
regeneration of sensory neurons. One type of sensory neuron is a mechanosensory nerve, which responds 
to physical touch and registers the sensation of pain. Von Frey fibers can be used to provide a precise 
mechanical pressure stimulation. The animals were tested prior to surgery and weekly following surgery. 
The results show the ratio between the experimental leg and contralateral leg. Prior to surgery all groups 
responded to the same force on both hind limbs. Immediately following surgery, all groups required higher 
stimulus force to elicit a response on the experimental side. At week 1-3 Fibers + GF + PT was significantly 
different than Fibers + PT. Autographs and GF groups fell below 1 at week 3 indicating hypersensitivity, 
which can indicate new nerve growth. It is unlikely, however, the nerves in the sciatic reconnected; the 
Figure 3-9: von Frey Mechanoreceptor Test. Calibrated fibers are used to test the pain threshold of animals pre- 
and post-surgery. Following surgery all groups lost sensory response in their injured leg. At 3 weeks autograph 
and GF groups showed a hypersensitivity, with the fibers groups following at 4 weeks. Statistical significance (p 
< 0.05): * Fibers + GF + PT differ from Fibers + PT; ○ Autograft different from all other groups. 
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response more likely suggests compensation from the sural nerve [177]. At week 5 & 7 Autograft is 
significantly different from all other groups, having nearly returned to its pre-surgery values. It is unclear 
if change is due to the regeneration of the sciatic nerve or continued growth of the sural nerve, additional 
information from other tests is needed. 
Static Sciatic Index 
 One of the main results of sciatic nerve transection in rats is the loss of functional control of the 
muscles that govern the movement of the toes. Animals with no injury will spread their toes wide to give 
the best support, while those with injuries will keep their toes tightly together. Following surgery all groups 
showed complete impairment, as expected. Over the course of 8 weeks the autograft group recovered the 
 
Figure 3-10: Static Sciatic Index (SSI). The sciatic index is a quantification of the severity of impairment in the 
sciatic nerve based on the animal’s ability to spread it toes. A value of 0 indicates no impairment, with -100 being 
complete impairment. Autograft animals show consistent improvement through the 8 weeks of the study. Fiber + 
PT has some improvement in week 7 and 8. All other groups show minimal change following week 1. Statistical 
significance (p < 0.05): # Fibers + PT differ from Fibers; * Fibers + GF + PT differ from Fibers + PT; ○ Autograft 
different from all other groups. 
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most. At week 2 Autograft and Fibers + PT were both significantly different than Fibers and Fibers + GF. 
In week 3 Autograft and Fibers + PT were both significantly different than Fibers + GF. Interestingly, the 
PT groups showed slightly higher performance during the weeks that they were using the treadmills. 
However, this is only significantly different for the groups without GF at week 2. After week 5 Autograft 
is significantly different than all other groups. After week 6 Fibers + PT are also significantly different than 
the other groups.  
Gastrocnemius Muscle Mass 
 One way to quantify the muscle atrophy is by mass. At the end of the study the gastrocnemius 
muscle was harvested bilaterally and weighed. All experimental groups show a 70-80% muscle loss, while 
the autograft group only showed a 50% loss. Interestingly, Fiber + PT was significantly different from the 
 
Figure 3-11: Gastrocnemius Muscle Mass. Muscle mass can indicate the amount of muscle atrophy that occurred 
due to injury. At the end of this study the Autograft group had 50% less muscle mass on the injured side, while 
the other groups had 75-80% less. Statistical significance (p < 0.05): ○ Autograft different from all other groups; 
* Fibers + GF + PT differ from Fibers + PT (p = 0.05) 
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Fibers + GF + PT group. Autograft was significantly different from all other groups. Because weights are 
only available at the end of the study, it is difficult to determine if the autograft group experienced similar 
muscle atrophy to the other groups earlier in the study. However, it is likely that they did and subsequently 
recovered some muscle mass as the muscle was reinnervated. Muscle fiber and neuromuscular junction 
analysis is needed to confirm this. 
Muscle Contractile Force 
 The strength of muscle contraction is related to the number of muscle fibers that activate during the 
contraction. Muscles begin to atrophy when they lose neural stimulation, therefore muscle atrophy is a 
 
Figure 3-12: Muscle Contractile Force. At the end of the study, a force transducer was used during electrical 
stimulation to measure the amount of force produced by the gastrocnemius muscle. The figure shows the ratio of 
the experimental side muscle to the contralateral side at various stimulation voltages. Low values indicate poor 
muscle strength on the injured side. Arrows indicate the voltage where that group has a peak in force ratio. 
Statistical significance (p < 0.05): * Fibers different from Auto, Fibers + GF, and Fibers + PT ;  # Fibers different 
from Autograft. 
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common side effect of peripheral nerve injury. Contractile strength can give an indication of how much the 
muscle has atrophied and the number of active neural muscular junctions that exist. As nerve connections 
to the muscle are restored the contractile force should also increase. For the spectrum of voltage ranges 
used the Autograft group show the strongest response, while the Fibers group showed the weakest. 
Interestingly, we see a peak in force for both GF groups at a higher voltage than we do for the groups that 
do not have growth factors. The experimental side was weaker than the contralateral side at all voltage 
levels. Fibers alone are significantly different than Fibers + PT, Fibers + GF + PT and Autograft at 0.6, 2, 
and 6 Volts.  
Compound Muscle Action Potential 
 Compound Muscle Action Potential (CMAP) can provide us with information about the 
effectiveness of the nerve signaling and the amount of muscle fiber that is innervated. Each muscle fiber 
has axons that connect to multiple different muscle fibers. Collectively, the nerve and muscles it innervates 
are referred to as a motor unit [50, 178]. The amount of force produced by a muscle depends on the number 
of motor units activated. The combination of action potentials that are signaling to motor units is the CMAP.  
A voltage sweep was used in this study to show the differences in motor unit activation. Since 
CMAP is an additive signal from multiple motor units or muscle fibers, a larger CMAP value indicates an 
increase in muscle fiber activity [179]. Several measurements were made from the recorded EMG signals. 
First, the area under the positive portion of the curve was measured. This gives an indication of the number 
of fibers that were firing. Next, the amplitude of the curve was calculated. Muscle fibers that are firing in 
sync, which is the normal response, create a taller and narrower impulse; a wider curve indicates fibers 
firing out of sync. To further describe the specific shape of the response, duration of the initial peak and the 
overall wave were calculated. The amplitude divided by the duration of the stimulated peak, referred to 
here as shape factor, can be compared to the normal condition. Finally, the latency of the peak was 
calculated. This indicates the amount of time from the stimulus to the action potential being created in the 
muscle. Selected voltages for each of the above parameters are shown in Figures 3-13 through 3-17 on the 
following pages. 
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In addition to the parameters calculated at each stimulation voltage, the voltage that elicited the 
strongest response was calculated for each group. For comparison the average minimum and average peak 
voltages from all the animal’s contralateral recordings is used as the control value. These values are 
summarized in Table 3-2.   
Table 3-2: Voltage Which Produces Strongest Response 
Parameter Control Auto Fibers Fibers+PT Fibers+GF Fibers+GF+PT 
Area .9 4 6 5 7 3 
Amplitude .9 4 7 5 8 5 
Duration .9 4 7 5 .9 .1 
Latency .9 .2 .2 .8 1 2 
 
 
Figure 3-13: Area of Compound Muscle Action Potential. The CMAP signal increases as more muscle fibers 
fire simultaneously. Arrows indicate where groups show a peak in area. The Fibers + GF + PT group shows the 
strongest response first at stimulation of 3V, while other experimental groups require more stimulation to reach 
the same area.  
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Area under the CMAP curve can indicate the number of fibers stimulated, while the amplitude 
provides information about how coordinated the signals are. For CMAP area at a stimulation of 5 V the 
Fibers + PT group is significantly higher than the Fibers + GF group. The stimulation voltage which has 
the peak response for each group is also important. In this case Fibers + GF + PT shows a peak at a lower 
stimulation voltage than all other experimental groups.  
CMAP Amplitude can indicate when the motor units are working together best. Again, the Fibers 
+ GF + PT group reaches a peak before others in the class. At 0.9 and 4 V the autograft group is significantly 
higher than all other groups.     
 
Figure 3-14: Amplitude of Compound Muscle Action Potential. The CMAP signal increases as more muscle 
fibers fire simultaneously. The Fibers + GF + PT group shows increasing amplitude at lower stimulation voltages 
than the other experimental groups. Arrows indicate were that group shows a peak in amplitude. Statistical 
significance (p < 0.05): ○ Autograft different from all other groups 
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 Another value that can be calculated for CMAP is the latency of the signal. Due to the short distance 
and corresponding short time to CMAP initiation, latency here is calculated from stimulation to the peak of 
the action potential. At stimulation voltages of 4 and 5 V the Fibers + GF group has a significantly shorter 
latency than the Fibers + PT group.  
 
 
Figure 3-15: Latency of Compound Muscle Action Potential. Latency is a measure of the time it takes for the 
signal to take effect. Shorter times indicate improved signal transmission.  
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 The amount of time the action potential is occurring, or duration, can also be calculated. Multiple 
factors can contribute to the duration. A strong action potential can lead to a longer recovery and thus a 
longer duration. This is likely what occurred with the autograft group. Alternatively, poor signaling leading 
to motor units firing out of sync could also lead to increased duration. This could be what occurred with the 
groups which didn’t receive growth factors. There were no significant differences in the duration data.   
 
 
Figure 3-16: Duration of Compound Muscle Action Potential. Duration is calculated from the onset of action 
potential until the signal stabilizes again. Duration can be increased by the strength of the action potential or by 
motor units firing out of sync.   
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Histology and Immunohistochemistry 
 H&E staining can provide a glimpse into the health of tissue. Cell cytoplasm is stained pink and 
nuclei are stained purple. Sample images of are provided in Figure 3-17. 
 
 
Figure 3-17: H&E Stained Longitudinal Slices. Sample slices for each treatment group and uninjured control. 
Cell nuclei can be seen throughout most tissue slices.  
65 
 
 
 
Immunohistochemistry can give more detailed information about the types cells present in a tissue 
sample. The cell types of interest are in nerve axon regeneration and the proliferation of support cells in the 
 
 
Figure 3-18: Immunohistochemistry. Nerve slices stained for Neurofilament (green), S100 (red), and DAPI 
(blue). Proximal end is on the left. S100 is seen most prominently in the uninjured control. 
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conduit. Neurofilament is a protein most commonly found in nerve cells, which can be used to identify 
neurons. Similarly, S100 is a protein that is readily expressed in many support cells such as Schwann cells. 
Prevalence of S100 near neurons indicates potentially myelinating cells being present in the system. (Figure 
3-18) 
Discussion 
 This study created a unique nerve growth conduit providing multiple cell growth signals and 
combined it with physical therapy in the form of treadmill running to improve functional recovery following 
peripheral nerve injury. The conduit consisted of an outer shell of PCL to provide structural integrity to 
prevent conduit collapse, which would restrict regeneration. Researchers have used many natural and 
synthetic materials to create conduits for nerve regeneration studies [77, 78]. PCL was selected because it 
is an FDA approved implantable material which degrades over more than 6 months by hydrolysis under 
normal physiological conditions; this allows the conduit to remain intact for the duration of nerve 
regeneration, while precluding the need for an additional surgery to remove it [180]. The aligned fibers are 
electrospun flat and then rolled to be oriented around the nerve. The rolling creates an outward pressure in 
the conduit to resist crushing, which is a primary design factor for nerve conduits.   
 PCL provides the structural support for the conduit, but nerves have been shown to prefer a 
substrate of lower mechanical stiffness, so it is not a mechanically ideal growth substrate for nerve tissue. 
HA was selected for the inner structure to provide that growth signal. The mechanical stiffness of HA can 
be modified through the precise addition of methacrylate sites, which are then used to crosslink the polymer. 
The HA of the inner structure was electrospun into aligned nanofibers to provide a topographical cue. 
Regenerating neurites have been shown to grow along aligned fibers and to prefer nano size fibers over 
larger fibers [93]. 
 Growth factors can also help to enhance nerve regeneration after injury; studies have shown that 
extended release of growth factors creates longer neurites. To allow for extended delivery, growth factor 
was encapsulated into PLGA microspheres. As proof of concept, only one growth factor was selected, 
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however, this model can easily be modified to include multiple growth factors in future studies. This study 
used a rat sciatic nerve injury model for testing and was focused on functional recovery. The sciatic nerve 
is a mixed nerve, containing both sensory and motor neurons. GDNF was selected as the growth factor 
because it has been shown to support both motor and sensory neurons specifically in the peripheral nervous 
system [78]. Based on the literature, Other growth factors that were considered included nerve growth factor 
(NGF), brain-derived neurotrophic factor (BDNF), and ciliary neurotrophic factor (CNTF), however GDNF 
appears to have the broadest benefit in the PNS for a mixed nerve [18, 181]. The production process and 
properties of the scaffold used for the internal structure of the conduit are similar to those reported by our 
group in a previous study [5, 170]. 
 Two different conduits were produced for this study: one in which the internal structure was only 
nanofibers (Fibers) and a second that contained nanofibers and growth factor releasing microspheres (Fibers 
+ GF). The second conduit can be seen in Figure 3-7. The PCL and HA layers are clearly visible as are the 
embedded microspheres. Conduits were implanted into a rat sciatic nerve model and the two different 
conduit groups were further divided into two groups that received physical therapy (Fibers + PT, Fibers + 
GF + PT) and two that did not (Fibers, Fibers + GF). For a control group a 10 mm segment of the nerve 
was removed and reversed to simulate an autograft (Autograft).  
 Throughout the two-month study animals were tested weekly to monitor motor and sensory 
function. First, gross motor skills were tested by having the animal walk across a ladder while the number 
of times they missed a rung was recorded. From the results shown in Figure 3-8, the Fibers + GF + PT 
group outperformed the Autograft group in the first two weeks, after which they were nearly consistent 
with the Autograft. The Fibers + GF group also performed close to Autograft in the first several weeks, 
while the groups without growth factors lagged behind. Additionally, at most timepoints the group receiving 
PT performed better than the corresponding group that did not. By week 5 the Fibers + PT group was similar 
to the control and GF groups. This result is consistent with previous studies which showed that rats receiving 
treadmill physical therapy and balance testing for 4 weeks performed at the same rate as controls, while 
those that did not receive training continued to miss rungs on the ladder [182]. These results indicate that 
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both growth factors and physical therapy support gross motor recovery, however they do not show an 
additive benefit to GF + PT. The Fibers + GF + PT only slightly outperformed the Fibers + PT and Fibers 
+ GF groups at week 2 and 5.  
 Sensory response to mechanical stimulus was tested using the von Frey fibers. The fibers provide 
a known amount of force which can be used to indicate pain recognition. As seen in Figure 3-9 the Autograft 
and both GF groups began showing hypersensitivity at 3 weeks, which is indicative of new neurite growth. 
All groups show this hypersensitivity at 4 weeks. Tests were done on the center of the paw; the sural nerve 
has been shown to extend to the center of the foot to compensate for the loss of the sciatic nerve by 4 weeks.  
T get a better understanding of the reinnervation from the sciatic nerve, the fifth toe needs to be tested [177]. 
Fifth toe data was collected for all groups at week 8 (not shown), however without baseline data for 
comparison it was inconclusive. Future studies will be done on the fifth toe throughout. 
 One of the functions of the sciatic nerve in rats is control of the muscles which govern their ability 
to spread their feet. This lead to the use of the Sciatic Function Index (SFI) to quantify the return of function 
after sciatic nerve injury in rats. To calculate the SFI, foot prints are measured for 3 parameters (Figure 3-
 
 
Figure 3-19: Sciatic Index Measurements. Three measurements are taken of the paw: inner toe spread (ITS) from 
the second to fourth toe; toe spread (TS) from the first to the fifth toe; and print length (PL) from the tip of the third 
toe to the heal. The values differ from a normal paw (A) to a paw with a sciatic nerve injury (B). The values are 
then used to calculate sciatic functional index (SFI) or static sciatic index (SSI). This figure has been reproduced 
freely under a Creative Commons Attribution license. © 2008 Reis et al. Originally published by Brazilian Journal 
of Physical Therapy. [15] 
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19): Print Length (PL), which is the length from the top of the middle toe to the heel; Toe Spread (TS), 
which is the distance from the tip of the first toe to the tip of the fifth toe; and Intermediate Toe Spread 
(ITS), which is the distance from the tip of the second toe to the tip of the fourth toe. A percentage difference 
between the experimental and contralateral sides is then calculated. The individual factors are then entered 
into an equation published by Bain in 1989 [183]. The resulting SFI has a range of 0, representing a fully 
functional sciatic nerve, to -100 representing complete impairment. Originally, this was done by dipping 
the rat’s feet in ink and allowing them to walk across a paper. However, this could be flawed by over or 
under application of the ink and smearing from the animal dragging feet. As technology advanced, 
researchers began using glass bottom tracks and mirrors to record the animal walking on video [184]. This 
method improved the ability to get clean prints, however it required high-speed and high-resolution 
cameras, which can be cost prohibitive. With both methods the experimental data collection was very time-
consuming as it required the animals to walk in a set path. Even with proper training in advance, animals 
could refuse to participate. More recently, researchers discovered that measurements taken from the animal 
while standing correlated closely to results received from the walking measurements, leading to the 
development of the Static Sciatic Index (SSI) [185]. This method allows images to be record of the animal 
while stationary in a glass bottom cage. Only a few seconds of video are required after the animal is allowed 
to acclimate to the recording cage. Also, the camera can be positioned much closer and it does not need to 
be as high quality. For these reasons, this is the method used in this study.  
 The SSI measurements recorded for the autograft group in this study, Figure 3-10, show the same 
upward trend from injury that is seen in most studies of sciatic nerve injury in the literature [138, 186-188]. 
Though the experimental groups showed little change over the duration of the study, there are some 
interesting points to note: first, in weeks 2 and 3 both PT groups show slight improvements from their week 
1 values and are above those for their corresponding no PT group. Following those weeks, the values drop 
to become similar to the no PT groups. The week 2 and 3 recordings fall into the 4 weeks when the PT 
groups are doing daily treadmill walking. This could indicate that the PT has some ability to delay the most 
sever impartment that results from sciatic injury. Another point to note is that in week 7 and 8 the Fiber + 
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PT and Fiber + GF group reach their highest value.  This could be the beginning of an upward trend 
indicating that these groups are starting to achieve reinnervation. This would indicate that a longer end 
point, or multiple end points, perhaps 8 and 16 weeks, would be preferred for future studies to more clearly 
see the differences between treatment groups. Another recent study looking at a 20 mm nerve gap also did 
not show improvement in treatment group SSI until after 4 weeks, however, that study saw the treatment 
group, which consisted of a collagen based conduit with Schwann Cells, catch up to the autograph by 8 
weeks[186]. 
The sensory and motor function tests recorded weekly throughout the study indicate that the 
addition of GFs or PT to the basic topographical and mechanical cue of the nanofibers speeds repair. 
However, there is no clear indication that the combination of both GFs and PT have any additional benefit. 
Additional analysis is required to support the functional testing and provide more insight into the amount 
of regeneration that is occurring.  
In this study we conducted electrophysiological recordings to determine if the regenerating nerves 
were able to produce and transmit action potentials that had a meaningful effect on the target muscles. 
Additionally, the gastrocnemius muscle and sciatic nerve were harvested for analysis. Looking first at the 
muscle weight, we can see that all of the treatment groups lost a large amount of muscle mass. The Autograft 
group has significantly higher experimental side muscle mass. However, the Fibers + PT is also 
significantly (p=0.05) heavier than the Fibers + GF + PT group. This would indicate that the muscle had 
less atrophy, which could lead to better muscle control in the foot, which supports what was seen in the SSI 
testing where the Fiber + PT group was beginning to recover at the final time points.  
Beyond just muscle size, the contraction force of the muscle following nerve stimulation can be 
examined. The Fibers only group had significantly lower experimental side contraction force, but little 
difference is seen between the other experimental groups. This parallels what was seen in the functional 
testing. CMAP recording can provide deeper understanding of what is happening within the muscle.  
This study used a range of stimulation voltages to give a full picture of the amount of stimulation 
that was required to produce functional action potentials. Considering the area under the CMAP curve, 
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Fibers + GF + PT has a peak of response around 3V, while other experimental groups peak later. This 
indicates that a lower stimulation is required to produce a peak in that group, which could indicate more 
myelinated nerve fibers.  
Higher amplitude of CMAP peaks can indicate the involvement of additional muscle fibers. The 
Fibers + GF + PT group shows a stronger response sooner than other groups, but is not significantly 
different. Analysis of neuromuscular junctions and muscle fiber size will be used to confirm the 
involvement of additional muscle fibers later.  
  Exact nerve conduction velocity cannot be calculated from CMAP due to the varied depth and path 
of propagation in the muscle fiber. However, latency, which is the amount of time between the stimulation 
and the resulting action potential recording can give an estimate of the nerve conduction. Mature myelinated 
fibers will conduct more quickly. The recording in this study show a significant difference between Fibers 
+ GF and Fibers + PT at 4 and 5 weeks. Additionally, though not significant, the latency for PT groups is 
longer than those for the corresponding non-PT group in all but 1 case. This increased latency might indicate 
that the motor neurons in the sciatic nerve are not maturing as quickly. Alternatively, the physical therapy 
could have helped encourage other nerves in the area to attempt to compensate. Thus, the increase in latency 
could result from the action potential propagating through another nerve to the gastrocnemius. Finally, 
considering duration of the CMAP waves, the PT groups have consistently longer durations than the non-
PT groups. The duration here measures from the beginning of the CMAP wave until it stabilizes again. The 
increased duration could be due to signals arriving at different times via varying nerve pathways.  
 Some of the conflicting results received could be cleared with additional end point CMAP 
recordings. Stimulating the nerve both proximal and distal to the conduit repair shows the health of both 
the sensory and motor neurons. Multiple muscles could also be recorded to reduce the contamination of 
signals with stimulus from other nerves.  
 Finally, immunohistochemistry and histology were performed on longitudinal slices of the nerve. 
H&E staining, which shows cell structure and nuclei, shows cells throughout all of the conditions. Looking 
closely at some of the slices, specifically from the examples in Figure 3-17 Fibers and Fibers + PT, voids 
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are seen in the cell staining; this is where the PCL conduit was. In the experimental groups we can also see 
that the tissue is not completely continuous throughout the conduit area. This study ended early in the nerve 
regeneration process, so complete nerve fibers aren’t expected to be seen throughout the slices. To clearly 
see where nerve cells were present fluorescent immunohistochemistry was also done. Neurofilament 200 
antibody with a green tag was used to highlight nerve fibers. S100 antibody with a red tag was used to 
identify Schwann Cells, and DAPI was used for nuclei. Colocations of Schwann Cells and nerves will 
appear orange. PCL autofluoresces also appearing green in the images. All conditions had DAPI throughout 
the conduit, indicating the presence of cells. Nerve tissue was present in all conditions, but the level of 
infiltration varied. Additional stains are needed to differentiate the conduit from the nerve fibers. Sample 
images in Figure 3-18 show the most neurofilament in the Fibers and Fibers + PT group. Very little S100 
was seen in the center of the conduits in the experimental groups. This is surprising as Schwann Cells assist 
in building paths for regenerating nerves to follow.  
Conclusion 
 This study compared several different elements that can affect peripheral nerve regeneration. First, 
the study indicated benefits of GDNF releasing microspheres. The footfall test showed that GDNF growth 
factor groups recovered gross motor function faster than their corresponding non-GDNF groups (Figure 3-
8). Additionally, the GDNF groups recovered sensory pain sensation faster (Figure 3-9). The contractile 
force also peaked at a lower stimulation indicating less voltage required to initiate coordinated muscle 
contraction (Figure 3-12).  
 Next, the study indicated benefits of physical therapy in the form of treadmill running. Groups 
receiving physical therapy performed slightly better on the footfall test than the corresponding group that 
did not receive physical therapy (Figure 3-8). At the beginning of the study, while the animals were still 
undergoing the daily treadmill running, the physical therapy groups had higher SSI scores than the 
corresponding non-physical therapy group (Figure 3-10). At the end of the study, the Fibers +PT group 
showed less muscle atrophy than other experimental groups (Figure 3-11). Both of the physical therapy 
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groups required lower stimulation voltage then their corresponding non-physical therapy group to reach 
peak muscle contraction force (Figure 3-12). 
 Finally, a couple of interesting points appear when looking at the combination of GDNF and 
physical therapy. In the footfall test the Fibers + GF + PT group had fewer misses than the other 
experimental groups at week 2 and 5, however the difference was not significant (Figure 3-8).  Additionally, 
that group had the lowest stimulation voltage required of experiment groups to reach its peak in both CMAP 
area under the curve (Figure 3-13) and CMAP amplitude (Figure 3-14).  
Functional testing in this study indicated faster recovery for groups that received GDNF or PT. 
However, a strong indication that the combination of the two creates a synergistic effect was not found. 
Additional information about the number and types of cells present in the conduit could provide more 
insight into the regeneration that occurred. This will be calculated from cross-sectional slices of the nerves 
at the proximal, center, and distal end of the conduits. Muscle tissue analysis will provide information about 
the number and quality of neural muscular junctions, which is an indicator of reinnervation. To allow for a 
clearer distinction between experimental groups a longer study will need to be conducted. The study should 
include multiple CMAP recordings. The results from this study further support the body of research that 
shows topographical, mechanical, and chemical cues can enhance nerve regeneration after peripheral nerve 
injury, and suggest further study is warranted to determine if there is a long term additive effect to the 
combination. 
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CHAPTER 4: FUTURE WORK: TAKING ELECTROSPUN SCAFFOLDS WITH GROWTH 
FACTOR RELEASING MICROSPHERES BEYOND PERIPHERAL NERVE INJURY 
Introduction 
This thesis provided a foundation for combing multiple cell signaling cues in an injury environment 
for improved recovery. While it specifically focused on peripheral nerve injury, there are many other injury 
environments that could benefit from similar systems. In its current form, the scaffold and microsphere 
(MS) system previously described has the potential to work with other growth factors (GFs) and have its 
mechanical properties tuned to be better suited to other tissue types.  By improving the GF release profile 
of this model, combining it with other promising therapies – such as stem cells – or using different materials, 
this novel system can be further developed in several ways. This chapter will discuss a few of the possible 
directions in which this work could proceed. 
Spatiotemporal Growth Factor Release 
The next step for this system is to produce more consistent MS, which would allow for more precise 
control of GF delivery. Many researchers have used microfluidics to produce MS in a very narrow size 
range [25, 189-191]. One device of particular interest, developed by Kong et al., provides the ability to 
predictably control the thickness of the MS shell simply by adjusting flow rates and osmolality of the three 
solutions in the device [25]. Figure 4-1 shows examples of the different droplets the system produced and 
the predicted and actual inner and outer diameters. Adjusting the thickness of the Poly-lactic-co-glycolic 
(PLGA) shell of the MS has a direct relationship to the breakdown of the microsphere and thus growth 
factor release [156]. Having the ability to precisely adjust the MS size and shell thickness leads to consistent 
breakdown and more tunable release profiles. We hypothesize that when these MSs are used in the 
electrospinning system described in earlier chapters, the distribution of microspheres in the scaffold will 
also be more uniform. This will result in a homogeneous growth factor profile throughout the scaffold and 
thus the conduit.  
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Homogeneous growth factor delivery is not necessarily the ideal model, which leads to the next 
advancement for this line of study: spatiotemporal release of multiple growth factors. The natural 
environment for nerve growth and regeneration has a very complex profile of growth factors. As an 
example, Fibroblast Growth Factor-2 (FGF2) is known to enhance nerve regeneration [8, 9, 24], but FGF2 
is only upregulated from day 0 to day 18 after PNI with a peak at day 7 [192, 193].  FGF2 is known to 
suppress myelination of axons and support axonal growth; though this may be ideal at the beginning of the 
nerve injury, having prolonged FGF2 exposure can lead to thinner myelin sheaths and a lack of resting 
Schwann cells [192, 193].  Brain Derived Neurotrophic Factor (BDNF) which is also known for enhancing 
nerve regeneration [8, 9], has an opposing effect to FGF2.  BDNF promotes Schwann cell differentiation 
to the myelination state[192], and is expressed from day 3 after PNI until approximately day 42 with a peak 
at day 28 [192, 194]. This example demonstrates the complexities of the release timing and interaction of 
just two growth factors that exist in the nerve growth environment. When we begin to consider that there 
are more than a dozen growth factors commonly associated with nerve regeneration all interacting with one 
 
Figure 4-1: Microfluidic Microsphere Production. Optical microscopic images of (A) microfluidic generation 
of W/O/W double emulsions; predicted inner droplet size d1 and the whole droplet size (blue symbols) and 
compared with size measured through image analysis (red symbols) for changing inner phase flow rate (Q1) (B) 
and middle phase flow rate (Q2) (C) while keeping other flow rates constant. Optical microscopic images of (D) 
microfluidic generation of monodisperse O/W/O double emulsion droplets in a modified geometry; predicted inner 
droplet size d1 and the whole droplet size d2 (blue symbols) and compared with sizes measured by image analysis 
(red symbols) for changing inner phase flow rate (Q1)  (E) and middle phase flow rate (Q2) (F) while keeping other 
flow rates constant. Reprinted from Kong, T., et al., Microfluidic fabrication of polymeric core-shell microspheres 
for controlled release applications. Acta Biomaterialia, 2013, with the permission of AIP Publishing. [25] 
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another in the microenvironment, the need for precise growth factor release control becomes clear (Table 
4-1).  
The system tested in this thesis can be modified to encapsulate any hydrophilic growth factor. 
Encapsulating multiple growth factors into MS with varying shell thicknesses and including them in a 
scaffold in different proportions is a step toward the precise spatiotemporal release needed to completely 
model the nerve growth environment. However, additional tools may be needed due to the complexity of 
the environment and the need to keep growth factors within the target area. One method is to sequester GFs 
in the scaffold fibers. GF sequestration is a naturally occurring phenomenon where heparin binding sites in 
the extracellular matrix bind free floating GFs. This is useful because it prevents the GF from being 
degraded while still being available to bind and signal cells. Heparin binding has been used in cardiac tissue 
[195] and nerve tissue[6, 109, 196] as a way to prolong GF delivery duration. By adding heparin to the 
methacrylated hyaluronic acid (MeHA) used as the scaffold fiber material, GF loss from the delivery site 
will be naturally slowed.  
Beyond the temporal aspect of GF release, this model could also have improved spatial delivery of 
GFs. While one important aspect described above is keeping the GF in the injury location, studies have also 
Table 4-1: Growth Factors used for Nerve Regeneration 
Growth Factor  Abbreviation Reference 
Neural Growth Factor* NGF [1-7] 
Brain Derived Neurotrophic Factor* BDNF [8, 9] 
Epidermal Growth Factor EGF [10, 11] 
Neurotrophic Factor 3* NT-3 [8, 9, 12] 
Neurotrophic Factor 4/5* NT-4/5 [8] 
Ciliary Neurotrophic Factor* CNTF [8, 20] 
Glial Cell Line-derived Growth Factor* GDNF [1, 22] 
Fibroblast Growth Factor-1* FGF-1 [8, 9, 23] 
Fibroblast Growth Factor-2* FGF-2 [8, 9, 24] 
Platelet Derived Growth Factor* PDGF [8] 
Glial Growth Factor* GGF [8, 26, 27] 
Vascular Endothelial Growth Factor* VEGF [8, 9] 
Leukemia Inhibitory Factor* LIF [8] 
Insulin-like Growth Factor* IGF-1 [8, 9] 
Transforming Growth Factor - β TGF-β [28] 
Tumor Necrosis Factor* TNF-α [8] 
*Growth factor was also in a table in a review [8], see original table for more sources.  
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shown that gradients of GFs can also help direct growth [197-201]. By electrospinning fibers from multiple 
sources onto the same mandrel we can produce gradients of MS within the scaffold material. Figure 4-2 
shows the electrospinning setup to achieve this gradient creation. Combining specifically tuned 
microspheres containing different GFs, delivered in a gradient, with sequestration via heparin binding 
creates a peripheral nerve regeneration scaffold system that is a close mimic to the natural environment. 
Artificial Spinal Cord Implant 
This work can also move beyond peripheral nerve regeneration to other tissues. Staying within the 
nervous system we can use aspects of this work to help address spinal cord injury (SCI). An estimated 2.5 
million people live with SCI, with over 100,000 new cases each year [202]. The results of these injuries 
vary by the location of the injury, but all result in catastrophic changes to patient’s functionality and can 
have a drastically negative affect on their quality of life. There are several similarities between peripheral 
nervous system regeneration and central nervous system regeneration, however, the central nervous system 
presents additional challenges: in the central nervous system, within hours of injury and continuing for 
several days, there is cell death of neurons and glial cells through both necrotic and apoptotic pathways 
[203-195]. This leads to the formation of a central fluid-filled cavity. Another challenge particular to SCI 
is the inhibitory scar that forms after injury and blocks regrowth of axons remaining near the injury site 
 
Figure 4-2: Gradient Electrospinning Setup. Gradient electrospinning is achieved by using multiple syringe 
pumps simultaneously, each containing a different solution.  By placing MS is in one solution, but not the other, 
a gradient of MS is created within the length of the scaffold. Image adapted from Ifkovits et. al. [17]  
Polymer A
Polymer B
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[206, 207]. Ascending sensory and descending motor axonal pathways still retain the capacity for growth 
but will slowly recede from the injury site [208]. These problems are most difficult to overcome when the 
spinal cord is completely severed, leaving no residual connections to the lower limbs. Studies have shown 
that providing scaffolding and stem cells to the gap can increase axonal growth, resulting in new neuronal 
relay-circuits, and/or improving cell survival [209-214]. However, there are no therapies that lead to 
substantial recovery and there has been little clinical success. In collaboration with Dr. Jean Peduzzi-Nelson 
a hydrogel implant for spinal cord injury was produced that incorporated this scaffold and MS model.  
The construct, referred to as an “artificial spinal cord” (ASC), consisted of three layers 
methacrylated hyaluronic acid (MeHA) fibers with stem cells inside of an MeHA hydrogel formed by photo 
cross-linking. Two layers of fibers contained opposing gradients of glial-derived neurotrophic factor 
(GDNF) and brain-derived neurotrophic factor (BDNF) releasing microsphere and had olfactory 
ensheathing cells grown on them. The remaining layer had fibers only with olfactory progenitor cells grown 
on them. The MeHA hydrogel solution also contained Chondroitinase ABC, which several preclinical 
studies have shown to help reduce scar formation and promote recovery by degrading chondroitin sulfate 
[206, 207].  
The ASC was tested in a rat model of spinal cord segment removal. The study included four 
treatment groups: 1) sham surgery - laminectomy only; 2) spinal cord segment removal, no graft; 3) 
hydrogel only after spinal cord segment removal; 4) ASC after spinal cord segment removal. The animals 
were tested weekly for 15 weeks using the Basso, Beattie and Bresnahan (BBB) locomotor rating scale, 
modified Hargreaves device, beam test, and inclined plane test. Additionally, in week 14 and 15 animals 
were tested using a ladder walk. For the ladder walk the placement of the foot was evaluated on a 0-7 scale, 
0 is when the rung is completely missed while 7 is correct placement. By the end of the 15 weeks, the ASC 
group BBB score had improved from complete impairment nearly to what is considered only ‘mild injury’ 
(Figure 4-3). The other functional tests also showed the ASC group significantly outperforming the other 
injury groups at most time points, indicating that both motor and sensory neurons were benefitting from the 
ASC (Figure 4-4).  
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This example goes beyond simply signaling nerve cells, but also attempts to help direct the action 
of support cells and direct differentiation of stem cells in the injury microenvironment. The results indicate 
that fibrous scaffolds with extended growth factor release from microspheres can be beneficial to not only 
support peripheral nerves, but the central nervous system as well. By further modifying the fiber and 
microsphere model, we can create a biomaterial scaffold that provides multiple signals to other tissue types 
as well.  
 
Figure 4-3: BBB Locomotor Test. Animals are rated on a scale of 0, complete impairment, to 21, normal 
function. The animals receiving the ASC greatly outperformed the hydrogel only and segment removal groups. * 
indicated ASC is significantly different then segment removal condition (p<0.05). +indicates ASC is significantly 
different then empty hydrogel condition (p<0.05). 
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Non-Nervous System Tissue 
 Biomaterial scaffolds are used to support cell growth in many injury environments. HA has 
been used in wound healing applications for decades due to its anti-inflammatory properties [215-218]. 
Both fibers and gels of HA are popular and used clinically, especially for particularly difficult wounds 
 
Figure 4-4: Functional Test Results. A. Beam walking test, smaller beam indicates less fear and better balance, 
B. Inclined plane, higher angle indicates higher grip in rear limbs, C. Hargreaves, shorter times indicate higher heat 
sensitivity, D. Ladder rung test, higher number indicates more normal foot placement. * indicated ASC is 
significantly different then segment removal condition (p<0.05). +indicates ASC is significantly different then 
empty hydrogel condition (p<0.05). In ladder rung test, ASC was significantly different then both other conditions. 
A B
C D
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[219]. Additionally, direct delivery of several GFs has also been shown to speed healing. Some of the 
growth factors involved with wound healing include vascular endothelial growth factor (VEGF), platelet-
derived growth factor (PDGF), basic fibroblast growth factor (bFGF), transforming growth factor-β (TGF-
β), insulin-like growth factor (IGF), and endothelial growth factor (EGF) [220-222]. A recent review 
looking over the various methods used to deliver GFs to the wound environment, noted that some of the 
most recent work has been in combining scaffolds and GF release to further improve results [221]. With 
some optimizations, including the spatiotemporal improvements mentioned earlier, our system could be 
used to precisely deliver GFs to the injury site with the added benefit of the HA’s anti-inflammatory 
characteristics. Similar work is already underway elsewhere; one example created an electrospun scaffold 
with GF releasing nanoparticles in the core of the nanofibers [223]. Another study used a spray production 
technique to create a fibrous scaffold that also incorporated GF releasing nanoparticles [222]. Both showed 
shortened wound healing time. 
Another possible target for an HA scaffold system is cartilage. Multiple studies have used HA 
based scaffolds or hydrogels as a delivery and support system for stem cells in cartilage repair [137, 224-
226]. One reason is that the substrate can be mechanically tuned to help direct stem cell differentiation 
[225]. The mechanical properties of our electrospun fibrous scaffolds can be tuned by adjusting the number 
of methacrylate sites which are then crosslinked.  We can also add additional support for cartilage repair 
by incorporating appropriate growth factors into microspheres in the scaffold [227].  Some examples of GF 
used in cartilage repair are TGF-β, IGF, FGF, and bone morphogenetic protein 2 (BMP-2) [228-231]. As 
with the scaffolds for other injury environments the precise combination of spatiotemporal release of 
growth factors and other cell signaling modalities will need to be carefully balanced to achieve optimal 
tissue repair. 
Other soft tissue repair studies have also utilized HA substrates. Some examples include heart valve 
repair, which benefited from valvular interstitial cells being cultured on HA hydrogels [232], vascular 
tissue, when combined with collagen [233], and even cornea repair [234]. These could also potentially 
benefit from the HA scaffold with microspheres model. In addition, this system has increased flexibility in 
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expanding beyond HA to other polymer materials as the electrospun fibrous substrate. Several natural and 
synthetic polymers have been used in electrospinning applications [235]. Moving further from the original 
design will require substantial reoptimization, but incorporating other polymers can extend the potential 
mechanical and adhesive properties of the system. 
Conclusion 
This thesis has presented a novel system to deliver multiple regenerative signals to peripheral 
nerves in vitro and in vivo. Specifically, we looked at mechanical cues, using crosslinked MeHA that’s 
mechanical properties can be adjusted by changing the amount of methacrylate sights which are added to 
the polymer. For nerves, a pliable substrate was selected. Topographical cues were created by 
electrospinning the MeHA into aligned nanofibers. Chemical cues were added by incorporating GF 
releasing microspheres into the scaffold. For in vivo study, exercise was included to provide the added 
benefit of physical therapy, which helps combat side effects of peripheral nerve injury and encourages the 
creation of new synapses. Improving the spatiotemporal control of the GF delivery could advance this work; 
we can further enhance its benefit by incorporating stem cells specific to the injury environment in which 
the system is being used. The topographical, mechanical, and chemical signals can be changed to make the 
system suitable for other tissue types, leading to potential treatment models for a number of injuries.  
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 Peripheral nerve injuries affect millions of people each year around the world. Current treatments include an 
autograft, the gold standard, and commercially available nerve growth conduits (NGC). Autografts have several 
drawbacks including donor site morbidity and nerve size mismatch, which leads to incomplete recovery. Commercial 
NGCs can help with recovery but do not contain any specific cues to guide nerve regeneration. This thesis first 
evaluated mechanical, topographical and chemical cues that can be included in a NGC to promote and direct nerve 
regeneration. To incorporate all of the cues, a compliant substrate methacrylated hyaluronic acid (MeHA, mechanical 
cue) is electrospun into aligned fibers (topographical cue), with poly-lactic-co-glycolic acid (PLGA) microspheres to 
deliver growth factors (GF, chemical cue).  
The properties of the scaffold were evaluated under physiological conditions using environmental scanning 
electron microscopy and mechanical testing in a physiological environment. The resulting scaffolds have hydrated 
porosities of 35-55% and young’s modulus from 0.43-2.86MPa. Nerve growth factor (NGF) was used as the GF for in 
vitro testing. The bioactivity of the encapsulated NGF was tested both during the short and long term. Results showed 
that NGF remains bioactive through the encapsulation and electrospinning process. ELISA showed that NGF is 
released from the microspheres for up to 4 weeks. Dorsal root ganglia (DRG) neurons were used to evaluate NGF 
bioactivity and testing showed that the released NGF was bioactive and could increase neurite outgrowth for up to 4 
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weeks. DRG testing on the scaffolds also showed that the combination of NGF released from the microspheres and 
the aligned nanofibers significantly directed and enhanced neurite outgrowth.  
The study continued with in vivo testing by creating an NGC that included the scaffold as an inner support 
mechanism. An additional cue was then added in the form of treadmill running, to simulate physical therapy (PT).  
Circumferentially aligned nanofibers of Polycaprolactone (PCL) were layered with longitudinally aligned electrospun 
methacrylated Hyaluronic Acid (MeHA) fibers, with or without microspheres containing glial cell line-derived 
neurotrophic factor (GDNF), and rolled into conduits with an inner diameter of 1.25mm and length of 14mm. The 
conduits were implanted into an 8mm sciatic nerve gap in female Lewis rats. The animals were divided into five groups: 
fibers, fibers + PT, fibers + GF, fibers + GF + PT, and autograft control. All animals received the following behavior and 
functional testing prior to surgery and weekly post-surgery: Static Sciatic Index, Von Frey Filament Mechanical Sensory 
Test, and Ladder Walking Test. At the end of the study Compound Muscle Action Potentials (CMAP) and contractile 
force of the gastrocnemius muscle was measured. Sciatic nerves were harvested bilaterally for histological analysis. 
Weekly testing showed that fibers with GFs enhanced or sped functional recovery. Footfall measures the number of 
times an animal misses a rung when traversing a ladder, indicating gross muscle control. By 4 weeks both the GF 
groups were performing similarly to the autograft. Von Frey fibers were used to test the sensory perception. All groups 
showed hypersensitivity similar to the autograft by week 4, however the GF groups showed a response pattern similar 
to the autograft at all time points. Sciatic Index testing showed some improvement over the 8 weeks of testing. The 
groups receiving GDNF had greater improvement than those that did not. CMAP showed similar results. 
Future work includes improvements to the microsphere production technique and additions of support cells to 
the system.  
  
108 
 
 
 
AUTOBIOGRAPHICAL STATEMENT 
Tonya Whitehead 
EDUCATION 
 
2017    PhD – Biomedical Engineering 
   Wayne State University, Detroit, MI 
 
2012   MS – Biomedical Engineering 
   Wayne State University, Detroit, MI 
 
2004   MS – Manufacturing and Engineering Management 
   Eli Broad College of Business, Michigan State University, East Lansing, MI 
 
2002   BS – Computer Engineering 
   Michigan State University, East Lansing, MI 
 
SELECTED PUBLICATIONS 
 
Peer Reviewed Journals 
Whitehead TJ, Avila COC, Sundararaghavan HG, “Combining Growth Factor Releasing 
Microspheres within Aligned Nanofibers Enhances Neurite Outgrowth”; Journal of Biomedical 
Materials Research: Part A 2017 Sep 23 
 
Whitehead TJ, Sundararaghavan HG, “Electrospinning Growth Factor Releasing Microspheres into 
Fibrous Scaffolds”; Journal of Visualized Experiments 2014 Aug 16:(90). 
 
Conference Proceedings 
Whitehead TJ, Mays EA, Peduzzi J, Mazhari A, Chen C, Cavanaugh JM, Sundararaghavan HG, “Improving 
Nerve Growth Conduits with Aligned Nanofibers, Growth Factors, and Physical Therapy”; Biomedical 
Engineering Society Annual Fall Meeting, October 2017, Podium 
 
Whitehead TJ, Potoff JJ, “Work in Progress: Self Directed Projects to Increase Engagement and Satisfaction 
in Basic Programming Course”; First Year Engineering Experience Conference, August 2017, Podium 
 
Whitehead TJ, Peduzzi J, Mazhari A, Chen C, Cavanaugh JM, Sundararaghavan HG, “Physical Therapy 
Combined with a PCL/HA Nanofiber Conduit for Enhanced Peripheral Nerve Repair”; Biomedical 
Engineering Society Annual Fall Meeting, October 2016, Podium 
 
AWARDS AND HONORS 
2017   Garrett T. Heberlein Excellence in Teaching Award  
2016   College of Engineering Three Minute Thesis (3MT) Winner 
2016   College of Engineering 3MT People’s Choice Winner 
2013-1915  King Chavez Parks Future Faculty Fellowship 
2014   Laureate, Tau Beta Pi, National Engineering Honor Society 
2012-2013  Thomas C Rumble University Graduate Fellowship 
